atomoxetine hydrochloride profile

Atomoxetine hydrochloride is a non-stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). It works by increasing the levels of norepinephrine in the brain, which helps to improve attention and focus. Atomoxetine hydrochloride is typically taken orally once daily. It is generally well-tolerated, but common side effects include decreased appetite, nausea, and insomnia. More serious side effects are possible, including liver problems, increased suicidal thoughts, and cardiovascular problems. Atomoxetine hydrochloride is synthesized through a multi-step process involving the reaction of 3-(2-amino-1-hydroxyethyl)phenol with 3,4-dichlorobenzoyl chloride. The resulting compound is then reacted with hydrochloric acid to form the hydrochloride salt. Atomoxetine hydrochloride is an important medication for the treatment of ADHD. It offers an alternative to stimulant medications, which can be problematic for some patients. Atomoxetine hydrochloride is studied extensively to understand its effects on the brain, its efficacy in treating ADHD, and its safety and tolerability. Researchers are also investigating the use of atomoxetine hydrochloride for other conditions, such as anxiety, depression, and Tourette's syndrome.'

Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

atomoxetine hydrochloride : The hydrochloride salt of atomoxetine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	54840
CHEMBL ID	1702
CHEBI ID	331697
SCHEMBL ID	122111
MeSH ID	M0124111

Synonym
MLS002153176
(r)-tomoxetine hydrochloride
(r)-(-)-tomoxetine hydrochloride
strattera
benzenepropanamine, n-methyl-gamma-(2-methylphenoxy)-, hydrochloride, (-)-
(-)-n-methyl-3-phenyl-3-(o-tolyloxy)propylamine hydrochloride
atomoxetine hydrochloride
ly-135252
ly-139603
ly-139602 [(+)-isomer]
atomoxetine hydrochloride [usan]
ly 139603
82248-59-7
strattera (tn)
D02574
tomoxetine hydrochloride
atomoxetine hydrochloride (jan/usp)
(r)-tomoxetine hydrochloride, solid
MLS001401377
smr000469177
atomoxetine hcl
CHEMBL1702
atomoxetine (as hydrochloride)
nsc-759104
(3r)-n-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine hydrochloride
chebi:331697 ,
(r)-n-methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine hydrochloride
unii-57wvb6i2w0
57wvb6i2w0 ,
nsc 759104
(r)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine hydrochloride
cas-82248-59-7
tox21_110292
dtxsid2044266 ,
dtxcid0024266
AKOS015920150
S3175
CCG-100874
HY-17385
atomoxetine (hydrochloride)
CS-1085
AM20060733
atomoxetine hydrochloride [usp-rs]
atomoxetine hydrochloride [ep monograph]
atomoxetine hydrochloride [mi]
atomoxetine hydrochloride [jan]
benzenepropanamine, n-methyl-.gamma.-(2-methylphenoxy)-, hydrochloride, (-)
atomoxetine hydrochloride [orange book]
atomoxetine hydrochloride [usp monograph]
atomoxetine hydrochloride [who-dd]
atomoxetine hcl [vandf]
atomoxetine hydrochloride [mart.]
SCHEMBL122111
(r)-n-methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine hcl
NC00124
NCGC00025345-02
tox21_110292_1
KS-1223
LUCXVPAZUDVVBT-UNTBIKODSA-N
(r)-(-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine hydrochloride
(r)-n-methyl-?-(2-methylphenoxy)-benzenepropanamine hydrochloride
methyl-((r)-3-phenyl-3-o-tolyloxy-propyl)-amine hydrochloride
mfcd06410992
hydrochloride, atomoxetine
hcl, atomoxetine
ly 139603 hcl
SR-01000763397-3
sr-01000597779
SR-01000597779-1
sr-01000763397
atomoxetine hydrochloride, united states pharmacopeia (usp) reference standard
(r)-n-methyl-gamma-(2-methylphenoxy)-benzenepropanamine hydrochloride
(r)-n-methyl-3-phenyl-3-(o-tolyloxy)propan-1-aminehydrochloride
atomoxetine for impurity a identification, european pharmacopoeia (ep) reference standard
atomoxetine hydrochloride, european pharmacopoeia (ep) reference standard
atomoxetine hydrochloride, pharmaceutical secondary standard; certified reference material
atomoxetine hydrochloride 1.0 mg/ml in methanol (as free base)
(r)-atomoxetine hydrochloride
SW197504-3
F0001-2408
HMS3677C05
HMS3413C05
Q27225729
(r)-n-methyl-3-phenyl-3-(o-tolyloxy)-propan-1-amine hydrochloride
atomoxetine, hcl
atomoxetine for impurity a identification
BM164222
atomoxetine hydrochloride- bio-x
methyl[(3r)-3-(2-methylphenoxy)-3-phenylpropyl]amine hydrochloride
EN300-18528139
benzenepropanamine, n-methyl-gamma-(2-methylphenoxy)-, hydrochloride, (-)
atomoxetine hydrochloride (usp monograph)
atomxetine hyrochloride
atomoxetine hydrochloride (ep monograph)
atomoxetine hydrochloride (usp-rs)
atomoxetine hydrochloride (mart.)
(3r)-n-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine monohydrochloride
(-)-n-methyl-gamma(2-methylphenoxy)benzenepropamine hydrochloride

Excerpt	Reference	Relevance
"Atomoxetine hydrochloride is an FDA-approved treatment for adult ADHD, but no studies have clarified whether there are advantages to once versus twice daily dosing."	( Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Adler, L; Allen, AJ; Bakken, R; Dietrich, A; Kelsey, D; Reimherr, FW; Sutton, VK; Taylor, LV, )	0.85

Excerpt	Reference	Relevance
" Serious adverse events have not been clearly associated with the drug, and there have been few discontinuations due to adverse events."	( Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Kratochvil, CJ; Wernicke, JF, 2002)	0.31
" The incidence of discontinuation-emergent adverse events was low and there were no statistically significant differences between the patients abruptly discontinuing from atomoxetine and those continuing on placebo."	( Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. Adler, L; Allen, AJ; Brown, WJ; Heiligenstein, J; Kelsey, D; Michelson, D; Milton, D; Ruff, D; Spencer, T; Wernicke, JF; West, SA, 2004)	0.32
" In addition, safety, adverse events, and vital sign measurements were assessed."	( Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. Adler, LA; Michelson, D; Milton, DR; Moore, RJ; Spencer, TJ, 2005)	0.33
" Adverse events consisted primarily of pharmacologically (noradrenergic) expected effects, such as increases in heart rate and blood pressure and a slight decrease in weight."	( Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. Adler, LA; Michelson, D; Milton, DR; Moore, RJ; Spencer, TJ, 2005)	0.33
" This review focuses on the tolerability, occurrence of adverse events, precautions required to prevent severe adverse events, and essential pharmacological interaction in the treatment of ADHD symptoms by non-stimulants."	( The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder. Banaschewski, T; Heise, CA; Himpel, S; Rothenberger, A, 2005)	0.33
" Treatment-emergent adverse events (TEAEs), laboratory values, vital signs, weight, electrocardiograms, scores on the Arizona Sexual Experiences Scale, and efficacy (using the Conners' ADHD Rating Scale-Investigator Rated: Screening Version) were assessed."	( Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Adler, L; Allen, AJ; Bakken, R; Dietrich, A; Kelsey, D; Reimherr, FW; Sutton, VK; Taylor, LV, )	0.13
"To compare the effects of two different methods for initiating atomoxetine in terms of the incidence of early adverse events."	( Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. Feldman, PD; Gao, H; Greenhill, LL; Newcorn, JH, 2007)	0.34
"Data on atomoxetine treatment-emergent adverse events in youths, ages 6 to 18 years, were analyzed from five randomized, double-blind, placebo-controlled, acute-phase studies."	( Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. Feldman, PD; Gao, H; Greenhill, LL; Newcorn, JH, 2007)	0.34
"During the first 2 weeks of treatment, fast/once daily titration patients showed higher rates of spontaneously reported adverse events than patients in the slow/twice daily titration group."	( Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. Feldman, PD; Gao, H; Greenhill, LL; Newcorn, JH, 2007)	0.34
" No spontaneously reported adverse events involving suicidal ideation or suicidal behavior occurred in either group."	( Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. Allen, AJ; Bangs, ME; Bartky, EJ; Busner, J; Carlson, C; Duesenberg, DA; Emslie, GJ; Harshawat, P; Kaplan, SL; Quintana, H; Ramsey, JL; Spencer, TJ; Sumner, CR, 2007)	0.34
" Marijuana dependent subjects taking atomoxetine experienced an inordinate number of gastrointestinal (GI) adverse events."	( Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Goldman, M; Kampman, KM; Lynch, K; Obrien, CP; Tirado, CF, 2008)	0.35
" There is considerable data suggesting that overall, the adverse effect burden from this use is dose dependent and is in the mild to moderate category, but few comprehensive reviews exist of the epidemiology of adverse effects alone."	( Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. Coghill, D; Graham, J, 2008)	0.35
" Adverse events and vital signs were assessed."	( Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. Adler, LA; Michelson, D; Moore, RJ; Spencer, TJ; Williams, DW, 2008)	0.35
" Adverse events consisted primarily of pharmacologically (noradrenergic) expected effects."	( Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. Adler, LA; Michelson, D; Moore, RJ; Spencer, TJ; Williams, DW, 2008)	0.35
" Safety was assessed based on adverse events (AEs)."	( Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. Gustafsson, PA; Hägglöf, B; Kadesjö, B; Poole, L; Svanborg, P; Thernlund, G, 2009)	0.35
"7%); however, there was no significant difference in discontinuation rates due to adverse events or lack of efficacy among these groups."	( Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Adler, L; Durell, T; Feldman, P; Jin, L; Schuh, L; Trzepacz, P; Walker, D; Wilens, T; Zhang, S, )	0.13
" Outcome measures were patient-reported treatment-emergent adverse events (AEs); discontinuations due to AEs, serious AEs, and changes in body weight, height, vital signs, electrocardiogram, and hepatic function tests."	( Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. Ball, SG; Bangs, M; Donnelly, C; Jin, L; Spencer, TJ; Trzepacz, P; Witte, MM; Zhang, S, 2009)	0.35
"Atomoxetine was safe and well tolerated for children and adolescents with > or = 3 and/or > or = 4 years of treatment."	( Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. Ball, SG; Bangs, M; Donnelly, C; Jin, L; Spencer, TJ; Trzepacz, P; Witte, MM; Zhang, S, 2009)	0.35
" These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality."	( European guidelines on managing adverse effects of medication for ADHD. Banaschewski, T; Buitelaar, J; Coghill, D; Danckaerts, M; Dittmann, RW; Döpfner, M; Graham, J; Hamilton, R; Hollis, C; Holtmann, M; Hulpke-Wette, M; Lecendreux, M; Rosenthal, E; Rothenberger, A; Santosh, P; Sergeant, J; Simonoff, E; Sonuga-Barke, E; Steinhausen, HC; Taylor, E; Wong, IC; Zuddas, A, 2011)	0.37
" Safety was assessed by adverse event (AE) monitoring, laboratory tests, vital signs, physical examinations, and electrocardiogram measures."	( Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. Abi-Saab, WM; Apostol, G; Bensman, L; Childress, A; Garimella, TS; Gault, LM; Hall, CM; Kratochvil, CJ; Olson, E; Robieson, WZ; Saltarelli, MD; Wilens, TE, 2011)	0.37
" ABT-089 was generally safe and well tolerated, with no statistically significant difference between any ABT-089 dose and placebo in the overall incidence of any specific AE, and no clinically significant changes in other safety measures."	( Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. Abi-Saab, WM; Apostol, G; Bensman, L; Childress, A; Garimella, TS; Gault, LM; Hall, CM; Kratochvil, CJ; Olson, E; Robieson, WZ; Saltarelli, MD; Wilens, TE, 2011)	0.37
" The adverse events reported by CYP2D610/10 subjects were indistinguishable from those of other Japanese participants."	( Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D610/10 genotype in healthy Japanese men. Azuma, J; DeSante, KA; Long, AJ; Matsui, A; Nakano, M; Read, HA; Sauer, JM; Smith, BP; Takahashi, M; Witcher, JW, 2012)	0.38
" The adverse events related to the therapy with IR-MPH, OROS-MPH or AHC were mild and the incidence rates of adverse events were not significantly different among the three groups."	( [Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review]. Lv, XZ; Shu, Z; Wu, SS; Zhan, SY; Zhang, YW, 2011)	0.37
"Our intensive pharmacosurveillance monitoring program was performed to increase the number of adverse drug reactions (ADRs) recorded in the Italian spontaneous reporting database, and to systematically collect more thorough data about atomoxetine (ATX) and methylphenidate (MPH) safety in the pediatric setting."	( Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Bravaccio, C; Capuano, A; Granato, R; Grimaldi, G; Panei, P; Parretta, E; Pascotto, A; Rafaniello, C; Rinaldi, B; Rossi, F; Ruggiero, S; Sportiello, L, 2012)	0.38
"From September 2007 to October 2010, 1841 youth were enrolled in the Italian Attention- Deficit/Hyperactivity Disorder Register, but we report here on the 76 children from the five Reference Prescription Centers in Campania, an Italian region where we administered our systematic adverse event checklist."	( Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Bravaccio, C; Capuano, A; Granato, R; Grimaldi, G; Panei, P; Parretta, E; Pascotto, A; Rafaniello, C; Rinaldi, B; Rossi, F; Ruggiero, S; Sportiello, L, 2012)	0.38
" While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs."	( Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E, 2013)	0.39
"The objective of this analysis was to provide additional information on the frequency, time to onset and time to resolution of sexual and genitourinary (GU) treatment-emergent adverse events (TEAEs) reported during atomoxetine treatment in clinical trials."	( Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. Arsenault, J; Camporeale, A; Day, KA; Kelsey, DK; Ruff, D; Williams, D, 2013)	0.39
" Tolerability and safety were assessed by monitoring treatment-emergent adverse events (TEAEs), height and weight, vital signs and electrocardiogram parameters."	( Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. Anderson, CS; Bloomfield, R; Caballero, B; Cardo, E; Civil, R; Coghill, D; Dittmann, RW; Higgins, N; Hodgkins, P; Lyne, A; Nagy, P, 2013)	0.39
"9% (37/233) of participants discontinued because of adverse events (AEs), primarily nausea (4."	( Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder. Allen, AJ; Goto, T; Hirata, Y; Ichikawa, H; Takahashi, M; Takita, Y; Trzepacz, PT, 2014)	0.4
"Short-term ATX treatment is safe and superior to placebo for overall ADHD symptoms and key secondary outcomes, with a medium ES."	( Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. Correll, CU; Schwartz, S, 2014)	0.4
"A bibliographic search was performed in the MEDLINE, EMBASE and PsycINFO databases for prospective studies evaluating the incidence of adverse events (AEs) in children and adolescents treated for ADHD."	( Safety of medicines used for ADHD in children: a review of published prospective clinical trials. Bonati, M; Clavenna, A, 2014)	0.4
" Safety analyses included treatment-emergent adverse events (TEAEs) and vital signs."	( Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder. Camporeale, A; D'Souza, D; Ghuman, J; Kratochvil, C; Lipsius, S; Tanaka, Y; Upadhyaya, H, 2015)	0.42
"Although limited by the small sample size of the external studies, these analyses suggest that in 5-year-old patients with ADHD, atomoxetine may improve ADHD symptoms, but possibly to a lesser extent than in older children, with some adverse events occurring at a higher rate in 5-year-old patients."	( Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder. Camporeale, A; D'Souza, D; Ghuman, J; Kratochvil, C; Lipsius, S; Tanaka, Y; Upadhyaya, H, 2015)	0.42
" Nausea, decreased appetite, and dry mouth were reported with significantly greater frequency by atomoxetine-treated patients, and only one placebo-treated patient discontinued because of adverse event."	( Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder. Bahn, GH; Goto, T; Hirata, Y; Hwang, JW; Kim, JH; Lee, JI; Lee, S; Lee, SI; Lee, YS; Park, TW; Shin, DW; Song, DH; Takahashi, M; Takita, Y; Treuer, T; Yook, KH, 2014)	0.71
" Statistically significantly more atomoxetine-treated than placebo-treated patients experienced treatment-emergent adverse events (81."	( Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials. Camporeale, A; De Bruyckere, K; Deberdt, W; Deix, C; Porsdal, V; Tanaka, Y; Upadhyaya, H, 2015)	0.42
" Safety assessments included treatment-emergent adverse events (TEAEs), electrocardiograms and vital signs."	( Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Bloomfield, R; Hervas, A; Huss, M; Johnson, M; Lyne, A; McNicholas, F; Robertson, B; Sikirica, V; Sreckovic, S; van Stralen, J, 2014)	0.4
" Common (≥5% frequency) treatment-emergent adverse events did not significantly differ between extensive/ultrarapid and intermediate metabolizers (odds ratios were <2."	( CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. Ahl, J; Fijal, BA; Goto, T; Guo, Y; Li, SG; Nisenbaum, LK; Tanaka, Y; Upadhyaya, HP, 2015)	0.42
"The aim of this study was to assess the type and frequency of adverse events (AEs) in children with attention-deficit/hyperactivity disorder (ADHD) treated with methylphenidate or atomoxetine over a 5-year period in a large naturalistic study."	( Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. Arcieri, R; Capuano, A; Chiarotti, F; Cortese, S; Curatolo, P; Germinario, EA; Margari, L; Panei, P, 2015)	0.42
"Adults with attention-deficit/hyperactivity disorder treated with atomoxetine were examined for time-to-onset and -resolution of common treatment-emergent adverse events (TEAEs) and male sexual dysfunction, and for changes in blood pressure (BP) and heart rate (HR) upon atomoxetine discontinuation."	( Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD. Allen, AJ; Escobar, R; Kryzhanovskaya, LA; Lane, JR; Lipsius, S; Tanaka, Y; Trzepacz, PT; Upadhyaya, H, 2015)	0.42
"Common adverse events (AEs) appeared early, within week 1 of atomoxetine treatment."	( Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD. Allen, AJ; Escobar, R; Kryzhanovskaya, LA; Lane, JR; Lipsius, S; Tanaka, Y; Trzepacz, PT; Upadhyaya, H, 2015)	0.42
" Withdrawals due to all-cause, adverse effects and lack of efficacy were defined as primary outcomes evaluating the safety of such medications."	( An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments. Gao, J; He, S; Li, Y; Wang, Q; Zhang, Y, 2017)	0.46
"Atomoxetine combined with motor training appears safe and may optimize motor training outcomes after stroke."	( Safety and improvement of movement function after stroke with atomoxetine: A pilot randomized trial. Carrico, C; Fleischer, A; Nichols, L; Powell, E; Sawaki, L; Ward, A; Westgate, PM, 2017)	0.46
" Outcomes like response rate, ADHD Rating Scale (ADHD-RS) score, and adverse events were compared between ATX and MPH treatments."	( Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials. Fang, Q; Liu, Q; Qin, L; Zhang, H, 2017)	0.46
"01]) and lower risk of adverse events (drowsiness: RR = 0."	( Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials. Fang, Q; Liu, Q; Qin, L; Zhang, H, 2017)	0.46
" We describe the rate and duration of adverse events in a randomized controlled trial of atomoxetine (ATX) and parent training (PT) for ADHD symptoms and noncompliance in children with ASD."	( Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism. Aman, MG; Arnold, LE; Brown, NV; Buchan-Page, KA; Corbett-Dick, P; Handen, BL; Hellings, J; Hollway, JA; Hyman, SL; Lecavalier, L; McAuliffe-Bellin, S; Pan, X; Rice, RR; Ryan, MM; Smith, T; Tumuluru, RV; Williams, C, 2017)	0.46
" Adverse events (AEs) were assessed through parent ratings of common symptoms on a seven-point Likert severity scale and through direct interviews with study medical staff."	( Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism. Aman, MG; Arnold, LE; Brown, NV; Buchan-Page, KA; Corbett-Dick, P; Handen, BL; Hellings, J; Hollway, JA; Hyman, SL; Lecavalier, L; McAuliffe-Bellin, S; Pan, X; Rice, RR; Ryan, MM; Smith, T; Tumuluru, RV; Williams, C, 2017)	0.46
" These may also be triggered by drugs and appear as adverse drug reactions (ADRs)."	( Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. Carnovale, C; Clementi, E; Gentili, M; Mazhar, F; Nobile, M; Peeters, GGAM; Pozzi, M; Radice, S, )	0.13
"We mined data from the US Food and Drug Administration Adverse Event Reporting System pharmacovigilance database, focused on methylphenidate, atomoxetine, amphetamine, lisdexamfetamine, and their derivatives."	( Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. Carnovale, C; Clementi, E; Gentili, M; Mazhar, F; Nobile, M; Peeters, GGAM; Pozzi, M; Radice, S, )	0.13
"We conclude that real-world data from the US Food and Drug Administration Adverse Event Reporting System are consistent with previous evidence from meta-analyses."	( Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. Carnovale, C; Clementi, E; Gentili, M; Mazhar, F; Nobile, M; Peeters, GGAM; Pozzi, M; Radice, S, )	0.13
"Atomoxetine, a selective norepinephrine (noradrenaline) reuptake inhibitor, is an effective medication in attention-deficit hyperactivity disorder with a generally well-tolerated adverse effect profile."	( A Severe Adverse Effect of Atomoxetine: Hypertensive Crisis. Guldiken, G; Karayagmurlu, A, )	0.13
" However, it may have moderate or severe toxic effects such as drowsiness, agitation, hyperactivity, tremors, tachycardia, hyperreflexia, hypertension, and seizures."	( Use of Intravenous Lipid Emulsion Therapy in a Case of Atomoxetine (Strattera®) Toxicity. Gün, E; Kocabay, K, 2020)	0.56
" Intravenous lipid emulsion therapy provides 'lipid sink' for toxic, lipophilic drugs, thereby effectively keeping toxic and lipophilic drugs out of the periphery."	( Use of Intravenous Lipid Emulsion Therapy in a Case of Atomoxetine (Strattera®) Toxicity. Gün, E; Kocabay, K, 2020)	0.56
" Prescribing information from the manufacturer lists genitourinary-related adverse events such as urinary hesitancy/retention and priapism as precautions for atomoxetine."	( Probable Genitourinary Adverse Events Associated With Atomoxetine in an Adult Male: A Case Report. Campbell, TJ; McGrane, IR, 2021)	0.62
"Although attention-deficit/hyperactivity disorder (ADHD) is widely studied, problems regarding the adverse effect risks and non-responder problems still need to be addressed."	( Synergistic efficacy and diminished adverse effect profile of composite treatment of several ADHD medications. Adil, KJ; Cheong, JH; Han, SH; Jeon, SJ; Kim, HJ; Kim, HY; Kim, R; Kwon, KJ; Mabunga, DFN; Park, D; Ryu, O; Shin, CY; Valencia, S, 2021)	0.62
" The goal is to analyze the adverse events (AE) associated with nonstimulant medications using post-marketing drug surveillance data."	( Retrospective analysis of adverse events associated with non-stimulant ADHD medications reported to the united states food and drug administration. Pang, L; Sareen, R, 2021)	0.62
" Trials of amphetamines, atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil with a placebo arm and reporting data on headache as an adverse event, were included."	( Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. Banaschewski, T; Bölte, S; Buitelaar, JK; Coghill, D; Cortese, S; Häge, A; Hohmann, S; Jonsson, U; Nobel Norrman, H; Pan, PY; Şahpazoğlu Çakmak, SS, 2022)	0.72

Excerpt	Reference	Relevance
"A pharmacokinetic profile of tomoxetine, a selective norepinephrine uptake inhibitor, was developed in human volunteers following single and multiple oral administrations."	( Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. Bergstrom, RF; Farid, NA; Lemberger, L; Parli, CJ; Ziege, EA, )	0.13
" Eligible patients could elect to participate in a single-dose or steady-state discontinuation pharmacokinetic evaluation including serial plasma sample collection over 24 hours."	( Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. Biederman, J; Heilgenstein, J; Long, A; Sauer, JM; Smith, B; Spencer, T; Wilens, T; Witcher, JW, 2003)	0.32
"Twenty-one cytochrome P450 2D6 extensive metabolizer patients participated in these single-dose and steady-state pharmacokinetic evaluations."	( Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. Biederman, J; Heilgenstein, J; Long, A; Sauer, JM; Smith, B; Spencer, T; Wilens, T; Witcher, JW, 2003)	0.32
" The oral bioavailability and clearance of atomoxetine are influenced by the activity of CYP2D6; nonetheless, plasma pharmacokinetic parameters are predictable in extensive and poor metaboliser patients."	( Clinical pharmacokinetics of atomoxetine. Ring, BJ; Sauer, JM; Witcher, JW, 2005)	0.33
" This method was used for sample analysis in a pharmacokinetic study of atomoxetine (25mg) in five healthy adult female volunteers."	( A new high performance liquid chromatographic method for quantification of atomoxetine in human plasma and its application for pharmacokinetic study. Nivsarkar, M; Padh, H; Patel, C; Patel, M; Rani, S, 2007)	0.34
" The validated method was successfully applied to a pharmacokinetic study in humans."	( Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. Bae, JW; Choi, CI; Jang, CG; Lee, HI; Lee, SY; Sohn, UD, 2012)	0.38
" After fixing three mechanism-specific pharmacodynamic parameters (I (max) and γ2 for NRI and γ1 for 5-HT(1A)) based on the model for atomoxetine and/or buspirone, the model fitted the exposure-response profiles of PF-04269339 and PF-03529936 well."	( Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist. Barta, N; Brodfuehrer, J; Campbell, B; Dounay, A; Gray, D; Haske, T; Lepsy, C; Li, CS; Zhang, L, 2012)	0.38
" The pharmacokinetic and pharmacodynamic profile of these drugs in plasma and cerebrospinal fluid (CSF) was assessed."	( A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition. Kielbasa, W; Pan, A; Pereira, A, 2015)	0.42
" Pharmacokinetic and pharmacodynamic data were obtained from healthy subjects (n = 160) from 5 clinical trials."	( Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. Kielbasa, W; Lobo, E, 2015)	0.42
" The Cmax and t1/2 for 4-HAT were lower and longer in the CYP2D610/10 group than those in the CYP2D6wt/wt group, but the AUC0-∞ was not different between these groups."	( Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites. Bae, JW; Byeon, JY; Chung, MW; Jang, CG; Jang, JH; Kim, IS; Kim, SH; Kim, YH; Lee, SY; Lee, YJ; Na, HS, 2015)	0.42
" Differences in pharmacokinetic parameters as well as clinical treatment outcomes across CYP2D6 genotype groups have resulted in dosing recommendations within the product label, but clinical studies supporting the use of genotype guided dosing are currently lacking."	( Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. Bishop, JR; Brown, JT, 2015)	0.42
" In this review, we have attempted to revisit and analyze all published clinical pharmacokinetic data on atomoxetine inclusive of public access documents from the new drug application submitted to the United States Food and Drug Administration (FDA)."	( Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. Li, GF; Markowitz, JS; Yu, G, 2016)	0.43
"Atomoxetine is the first non-stimulant drug to be approved for the treatment of ADHD, while the effect of myricetin on the pharmacokinetic of atomoxetine in rats or human is still unknown."	( The Effect of Myricetin on Pharmacokinetics of Atomoxetine and its Metabolite 4-Hydroxyatomoxetine In Vivo and In Vitro. Hu, GX; Hu, XX; Lan, T; Liang, BQ; Pan, WH; Yuan, LJ; Zhou, Q, 2017)	0.46
" Therefore, the present study investigated a possible pharmacokinetic interaction between atomoxetine (ATX), a treatment option for ADHD, and an antidepressant, namely, fluvoxamine (FVX)."	( Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Todor, I; Vlase, L, 2017)	0.46
" Non-compartmental methods were employed to determine the pharmacokinetic parameters of ATX and its main active metabolite (glucuronidated form), 4-hydroxyatomoxetine-O-glucuronide."	( Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Todor, I; Vlase, L, 2017)	0.46
" The presence or absence of any clinical consequences associated with this pharmacokinetic drug-drug interaction needs to be established in future studies."	( Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Todor, I; Vlase, L, 2017)	0.46
"Physiologically based pharmacokinetic (PBPK) modeling of drug disposition and drug-drug interactions (DDIs) has become a key component of drug development."	( Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions. Huang, W; Isoherranen, N; Nakano, M; Ragueneau-Majlessi, I; Sager, J, 2017)	0.46
"We propose a novel semi-automatic approach to design biomarkers for capturing pharmacodynamic effects induced by pharmacological agents on the spectral power of electroencephalography (EEG) recordings."	( Semi-Automated Biomarker Discovery from Pharmacodynamic Effects on EEG in ADHD Rodent Models. Cichocki, A; Hasegawa, M; Hiroyama, S; Horiuchi, M; Jurica, P; Li, J; Nishitomi, K; Ogawa, K; Struzik, ZR; Takahara, Y; Yokota, T, 2018)	0.48
" The aim of this study was to to develop a pharmacologically based pharmacokinetic (PBPK) model of atomoxetine in different CYP2D6 genotypes."	( Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes. Byeon, JY; Jang, CG; Kim, SH; Kim, YH; Lee, CM; Lee, SY; Lee, YJ, 2018)	0.48
" Simple physiologically based pharmacokinetic (PBPK) models and compartment models were set up to account for drug monitoring results of 33 Japanese patients (6-15 years of age) to help establish the correct dosage for the evaluation of clinical outcomes."	( Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6. Nakano, A; Notsu, Y; Ota, M; Sasaki, T; Shimizu, M; Yamazaki, H; Yoshida, S, 2020)	0.56
" While each of these medications have their own distinct pharmacokinetic profile, the extent to which pharmacogenetics effects their pharmacokinetic parameters is best described in atomoxetine, followed by methylphenidate."	( The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications. Brown, JT, 2022)	0.72

Excerpt	Reference	Relevance
" Possible explanations include atypical atomoxetine effect, excess atomoxetine or metabolites due to poor metabolizer status (CYP 2D6 polymorphism/deficiency), a drug-drug interaction leading to elevated drug levels or to excess synaptic norepinephrine or dopamine."	( Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Bond, GR; Garro, AC; Gilbert, DL, 2007)	0.34
" The aim of this study was therefore to evaluate the efficacy of ATX using standard variables of a computer-based continuous performance test (cb-CPT) combined with an infra-red motion-tracking device at different times of the day."	( Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tra Banaschewski, T; Dittmann, RW; Otto, WR; Schacht, A; Wehmeier, PM; Wolff, C, 2011)	0.37
"We clarified the safety, feasibility, and efficacy of atomoxetine administration combined with intensive speech therapy (ST) for patients with post-stroke aphasia."	( Atomoxetine administration combined with intensive speech therapy for post-stroke aphasia: evaluation by a novel SPECT method. Abo, M; Kakuda, W; Momosaki, R; Yamada, N; Yamamoto, K, 2016)	0.43
"Physiologically based pharmacokinetic (PBPK) modeling of drug disposition and drug-drug interactions (DDIs) has become a key component of drug development."	( Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions. Huang, W; Isoherranen, N; Nakano, M; Ragueneau-Majlessi, I; Sager, J, 2017)	0.46

Excerpt	Reference	Relevance
" Atomoxetine was well absorbed from the gastrointestinal tract and cleared primarily by metabolism with the majority of its metabolites being excreted into the urine, 66% of the total dose in the rat and 48% in the dog."	( Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. Barbuch, RJ; Conrad, PC; Kuo, F; Li, Q; Mattiuz, EL; Mullen, JH; Ponsler, GD; Sauer, JM; Shugert, RL; Wheeler, WJ; Wood, PG, 2003)	0.6
" Atomoxetine was well absorbed from the gastrointestinal tract and cleared primarily by metabolism with the preponderance of radioactivity being excreted into the urine."	( Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Desante, KA; Long, AJ; Mattiuz, EL; Ponsler, GD; Sauer, JM; Thomasson, HR; Witcher, JW, 2003)	0.6
" Absolute oral bioavailability ranges from 63 to 94%, which is governed by the extent of its first-pass metabolism."	( Clinical pharmacokinetics of atomoxetine. Ring, BJ; Sauer, JM; Witcher, JW, 2005)	0.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Moreover, in vitro taste evaluation method was established and ATX bioavailability was investigated employing pharmacokinetic studies."	( Taste masking of water-soluble drug by solid lipid microspheres: a child-friendly system established by reversed lipid-based nanoparticle technique. Huang, R; Li, H; Quan, D; Shen, L; Wang, T; Wang, Y; Zhang, Y; Zhang, Z, 2020)	0.56
" Taste assessment revealed that ATX-RLBN-SLM could efficiently mask the bitter taste and improved the bioavailability of ATX."	( Taste masking of water-soluble drug by solid lipid microspheres: a child-friendly system established by reversed lipid-based nanoparticle technique. Huang, R; Li, H; Quan, D; Shen, L; Wang, T; Wang, Y; Zhang, Y; Zhang, Z, 2020)	0.56
"Atomoxetine hydrochloride-reversed lipid-based nanoparticle-solid lipid microsphere exhibited excellent taste-masking effect with negligible leakage in the oral cavity environment and thorough collapse upon lipase stimulation, simultaneously enhancing the bioavailability of ATX."	( Taste masking of water-soluble drug by solid lipid microspheres: a child-friendly system established by reversed lipid-based nanoparticle technique. Huang, R; Li, H; Quan, D; Shen, L; Wang, T; Wang, Y; Zhang, Y; Zhang, Z, 2020)	2

Excerpt	Relevance	Reference
"For patients with attention-deficit/hyperactivity disorder who have hepatic impairment, dosage adjustment is recommended."	( Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Chalon, SA; Desager, JP; Desante, KA; Frye, RF; Golnez, JL; Horsmans, Y; Long, AJ; Sauer, JM; Smith, BP; Thomasson, HR; Witcher, J, 2003)	0.32
" Minimal accumulation occurred in plasma after multiple twice-daily dosing in extensive metabolizer pediatric patients, as expected based on single-dose pharmacokinetics."	( Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. Biederman, J; Heilgenstein, J; Long, A; Sauer, JM; Smith, B; Spencer, T; Wilens, T; Witcher, JW, 2003)	0.32
" Methylphenidate and amphetamine-based stimulants are now available in longer-acting, once-daily and shorter-acting divided dosing schedules."	( Pharmacological management of attention-deficit hyperactivity disorder. Reeves, G; Schweitzer, J, 2004)	0.32
") criteria, were randomized to receive 8 weeks of treatment with atomoxetine or placebo, dosed once daily in the mornings."	( Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Allen, AJ; Casat, CD; Coury, DL; Gonzales, J; Kelsey, DK; Malcolm, SK; Quintana, H; Saylor, KE; Schuh, KJ; Sumner, CR; Sutton, VK, 2004)	0.32
" No significant differences between once-a-day and twice-a-day dosing were found."	( Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. Allen, AJ; Faries, DE; Kelsey, DK; Kratochvil, CJ; Perwien, AR; Sumner, CR, 2004)	0.32
" The rates of adverse events in the trials were similar for both the once- and twice-daily dosing regimens."	( Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Christman, AK; Fermo, JD; Markowitz, JS, 2004)	0.32
"The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions, dosage and administration, and place in therapy of atomoxetine in the treatment of attention-deficit/hyperactivity disorder (ADHD) are reviewed."	( Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Corman, SL; Culley, CM; Fedutes, BA, 2004)	0.32
" Once-daily dosing of atomoxetine has been shown to be effective in providing continuous symptom relief."	( Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Barton, J, 2005)	0.33
"The newer treatments for ADHD offer advantages over immediate-release methyphenidate in dosing schedule and duration of action that may be of particular benefit to adolescent and adult patients."	( Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder. Hazell, P, 2004)	0.32
" Upon multiple dosing there is plasma accumulation of atomoxetine in poor metabolisers, but very little accumulation in extensive metabolisers."	( Clinical pharmacokinetics of atomoxetine. Ring, BJ; Sauer, JM; Witcher, JW, 2005)	0.33
" After adjustment of the dosage for body weight, the pharmacokinetic parameters are similar across all age and gender groups."	( [Current evidence about atomoxetine. A therapeutic alternative for the treatment of attention deficit hyperactivity disorder]. Peña, JA; Velásquez-Tirado, JD, )	0.13
" Placebo dosing was identical."	( Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Allison, DB; Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2006)	0.33
"Data indicate both dosing strategies are safe, well tolerated, and efficacious in the treatment of adult ADHD."	( Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Adler, L; Allen, AJ; Bakken, R; Dietrich, A; Kelsey, D; Reimherr, FW; Sutton, VK; Taylor, LV, )	0.13
" Symptoms remained improved up to 24 months without dosage escalation."	( Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. Feldman, PD; Gao, H; Kratochvil, CJ; Levine, LR; Newcorn, JH; Rogers, AK; Thomason, CK; Wilens, TE, 2006)	0.33
" Multiple dosing of 80 mg qd atomoxetine was well tolerated in this study."	( Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. Bangs, ME; Cui, YM; Long, AJ; Pan, AX; Teng, CH; Wise, SD; Yeo, KP; Yuen, E; Zhao, X; Zhou, Y, 2007)	0.34
" Side effects of stimulants are generally mild, short lived, and responsive to adjustments in dosage or timing."	( Changes and challenges: managing ADHD in a fast-paced world. Bukstein, OG; Crismon, ML; Manos, MJ; Tom-Revzon, C, 2007)	0.34
" Treatment with the higher dosage (9 mg/kg) of atomoxetine resulted in animals that were not significantly different than injured-vehicle treated animals."	( Post-injury atomoxetine treatment improves cognition following experimental traumatic brain injury. Hamm, RJ; Reid, WM, 2008)	0.35
" The disadvantages of such formulations include the need for multiple daily dosing and a potential for abuse."	( Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Findling, RL, 2008)	0.35
"Currently available treatments for ADHD in children are efficacious and well tolerated, but many of them are limited by the requirement for multiple daily dosing and abuse potential."	( Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Findling, RL, 2008)	0.35
" Group 1 (16 patients) received atomoxetine (strattera) in daily dosage 0,8-1,2 mg/kg as a monotherapy for 6 weeks."	( [Atomoxetine and piracetam in the treatment of attention deficit hyperactivity disorder in children]. Suvorinova, NIu; Zavadenko, NN, 2008)	0.35
" Morning dosing was superior to evening dosing on some efficacy measures."	( Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Allen, AJ; Block, SL; Coury, D; Kelsey, D; Lewis, D; Quintana, H; Schuh, K; Sumner, C; Sutton, V, 2009)	0.35
" Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults."	( Open-label trial of atomoxetine hydrochloride in adults with ADHD. Areskoug, B; Cederlund, M; Gillberg, C; Johnson, M; Råstam, M, 2010)	0.68
" A linear dose-response and vital signs similar to those from other atomoxetine studies were observed."	( A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. Allen, AJ; Hayashi, T; Ichikawa, H; Kambayashi, Y; Koeda, T; Oki, J; Saito, K; Takahashi, M; Takeshita, K; Takita, Y; Yamazaki, K, 2009)	0.35
" Dexmethylphenidate XR is a stimulant treatment in a single isomer form, and has an efficacy and tolerability similar to two doses of immediate-release (IR) dexmethylphenidate when taken 4 hours apart, but is dosed at half of the usual d,l-methylphenidate dose."	( Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Kratochvil, CJ; May, DE, 2010)	0.36
"This study compared two atomoxetine titration dosing schedules and two atomoxetine maintenance doses for treating adolescent attention-deficit/hyperactivity disorder (ADHD) inattention and hyperactivity/impulsivity."	( Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. Greenbaum, M; Herbert, M; Melmed, RD; Schuh, K; Wietecha, LA; Williams, DW, 2009)	0.35
" Unfortunately, results of current ADHD pharmacogenetic studies have not been entirely consistent, possibly due to differences in study design, medication dosing regimens and outcome measures."	( Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. Froehlich, TE; McGough, JJ; Stein, MA, 2010)	0.36
"To develop a descriptive profile of attention-deficit/hyperactivity disorder (ADHD) pharmacological treatment patterns in terms of persistence, adherence, augmentation, switching, and dosing changes; and to assess differences in treatment patterns with regard to ADHD medication type, class, and duration of action."	( Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Christensen, L; Harley, C; Hodgkins, P; Sasané, R; Tetali, S, 2010)	0.36
"Pharmacological treatment for attention deficit hyperactivity disorder, although highly effective, presents a marked variability in clinical response, optimal dosage needed and tolerability."	( A current update on ADHD pharmacogenomics. Genro, JP; Hutz, MH; Kieling, C; Rohde, LA, 2010)	0.36
" Patients in the highest-risk quartile for each category of behavior or domain were included and the dosing groups combined."	( Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD. Greenbaum, M; Saylor, K; Schuh, KJ; Wietecha, L; Williams, DW, 2010)	0.36
"A total of 55 subjects with PD and an Inventory of Depressive Symptomatology-Clinician (IDS-C) score > or = 22 were randomized to 8 weeks of atomoxetine or placebo treatment (target dosage = 80 mg/day)."	( Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Colcher, A; Duda, JE; Horn, SS; Hurtig, HI; Mamikonyan, E; Mavandadi, S; Nazem, S; Siderowf, AD; Stern, MB; Ten Have, TR; Weintraub, D, 2010)	0.36
"This interventional study provides Class II evidence that atomoxetine (target dosage = 80 mg/day) is not efficacious in improving clinically significant depression in PD."	( Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Colcher, A; Duda, JE; Horn, SS; Hurtig, HI; Mamikonyan, E; Mavandadi, S; Nazem, S; Siderowf, AD; Stern, MB; Ten Have, TR; Weintraub, D, 2010)	0.36
"MPH and ATM generally produced inverted-U dose-response curves, with improvement occurring at moderate doses, but not at higher doses."	( Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors. Arnsten, AF; Gamo, NJ; Wang, M, 2010)	0.36
"Attainment of a stable dosing regimen was defined as no change in type of drug (including a switch from an immediate release (IR) to a long-acting (LA) formulation), strength, and number of pills per day for five consecutive dispensings."	( Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. Hodgkins, P; Meijer, W; Sasané, R, 2010)	0.36
"This secondary analysis examined the efficacy and tolerability of atomoxetine (ATX) dosed once (QD) versus twice (BID) daily in 55 children aged 6-12 with attention-deficit/hyperactivity disorder (ADHD)."	( A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder. Akinnusi, O; Pelham, WE; Waschbusch, DA; Waxmonsky, JG, 2011)	0.37
"There were 22 subjects (40%) who switched to BID dosing at midpoint (mean dose = 1."	( A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder. Akinnusi, O; Pelham, WE; Waschbusch, DA; Waxmonsky, JG, 2011)	0.37
" The purpose of this study was to examine atomoxetine pharmacokinetics, safety, tolerability, and the effect of the CYP2D610/10 genotype after single-stepped dosing (10, 40, 90, or 120 mg) and at steady state (40 or 60 mg twice a day for 7 days) in 49 healthy Japanese adult men."	( Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D610/10 genotype in healthy Japanese men. Azuma, J; DeSante, KA; Long, AJ; Matsui, A; Nakano, M; Read, HA; Sauer, JM; Smith, BP; Takahashi, M; Witcher, JW, 2012)	0.38
"7 years) were randomly assigned to a daily dosage of up to 80 mg atomoxetine (Atx) or waiting list for 12-weeks."	( A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Alm, B; Baehr, C; Dittmann, RW; Sabljic, D; Skopp, G; Sobanski, E; Strohbeck-Kuehner, P, 2012)	0.38
" The two lower dosages showed a good tolerability profile, but the higher dosage of bavisant was less well tolerated, as evidenced by the incidence of total TEAEs (61."	( Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. Cooper, K; Daly, EJ; Gassmann-Mayer, C; Pandina, GJ; Weisler, RH, 2012)	0.38
" We aimed to study the excretion profile of ATX and its principal metabolites 4-hydroxyatomoxetine (4-OH-ATX) and N-desmethylatomoxetine (desmethyl-ATX) in oral fluid and plasma of ADHD paediatric subjects, after administration of different dosage regimens."	( Concentrations of atomoxetine and its metabolites in plasma and oral fluid from paediatric patients with attention deficit/hyperactivity disorder. Farré, M; Garcia-Algar, O; Marchei, E; Pacifici, R; Papaseit, E; Pichini, S, 2013)	0.39
" Clinical predictors of sleep problems during pharmacotherapy include age, sleep problems prior to initiating treatment, and dose and dosing schedule."	( ADHD treatments, sleep, and sleep problems: complex associations. Hlavaty, L; Stein, MA; Weiss, M, 2012)	0.38
" Ten second electrocardiograms were obtained for time-matched baseline on days -2 and -1, three time points after dosing on day 1 for moxifloxacin and five time points on day 7 for atomoxetine and placebo."	( Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. Allen, AJ; April, J; Beasley, CM; Haber, H; Jin, L; Kauffman, L; Kothare, PA; Loghin, C; Mitchell, MI, 2013)	0.39
" The aim of this study was to describe the excretion profile of ATX and its metabolites 4-hydroxyatomoxetine (4-OH-ATX) and N-desmethylatomoxetine (N-des-ATX) in sweat following the administration of different dosage regimens (60, 40, 35, and 18 mg/day) of ATX to six paediatric patients."	( Sweat testing for the detection of atomoxetine from paediatric patients with attention deficit/ hyperactivity disorder: application to clinical practice. Bilbao, A; Farré, M; Garcia-Algar, O; Marchei, E; Pacifici, R; Papaseit, E; Pichini, S, 2013)	0.39
"0 weeks, mean daily ATX dosage was 71."	( Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine. Alm, B; Dittmann, RW; Sabljic, D; Skopp, G; Sobanski, E; Strohbeck-Kühner, P; Wehmeier, PM, 2013)	0.39
" change in the ADHD rating scale, fourth edition [ADHD-RS-IV] total score from baseline) was compared between each GXR dosing group and the ATX group."	( Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Chen, KS; Erder, MH; Hodgkins, P; Lu, M; Signorovitch, JE; Sikirica, V; Wu, EQ; Xie, J, 2012)	0.38
" The time to onset of the most common TEAEs in adult male patients tended to occur relatively early in dosing: within the first 2 weeks for GU TEAEs, and during the second and third week of dosing for erectile and ejaculation issues."	( Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. Arsenault, J; Camporeale, A; Day, KA; Kelsey, DK; Ruff, D; Williams, D, 2013)	0.39
" In this open-label, dose-escalation study, patients received atomoxetine orally once daily over a period of eight weeks, starting at 40 mg/day (one week) up to a maximum dosage of 120 mg/day."	( Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder. Chung, SK; Gau, SS; Goto, T; Takahashi, M; Takita, Y; Wang, Y, 2014)	0.66
" Similar results were observed in MAIC sensitivity analyses evaluating other dosage ranges and using more heterogeneous trial populations (e."	( Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. Dammerman, R; Erder, MH; Findling, RL; Hodgkins, P; Lu, M; Signorovitch, J; Sikirica, V; Wu, EQ; Xie, J, 2013)	0.39
" Results were consistent in a variety of dosage range comparisons and within increasingly heterogeneous trial populations."	( Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. Dammerman, R; Erder, MH; Findling, RL; Hodgkins, P; Lu, M; Signorovitch, J; Sikirica, V; Wu, EQ; Xie, J, 2013)	0.39
"Examine how different dosing schedules and recent stimulant therapy effect incidence, time to onset, and duration of common treatment-emergent adverse events (TEAEs) during atomoxetine treatment."	( Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. Allen, AJ; Greenhill, LL; Newcorn, JH; Ruff, DD; Wietecha, LA, 2013)	0.39
"In pediatric patients, the most commonly reported TEAEs were abdominal pain, decreased appetite, fatigue, nausea, somnolence, and vomiting; time to onset of TEAEs was significantly shorter for once-daily versus twice-daily dosing for all TEAEs (P ≤ ."	( Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. Allen, AJ; Greenhill, LL; Newcorn, JH; Ruff, DD; Wietecha, LA, 2013)	0.39
"Time to onset and resolution of TEAEs appear dependent on dosing schedule and titration speed."	( Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. Allen, AJ; Greenhill, LL; Newcorn, JH; Ruff, DD; Wietecha, LA, 2013)	0.39
"These findings may help clinicians assess factors upon initiation of ADHD treatment to improve course prediction, proper dosing and treatment adherence and persistence."	( Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates. Altin, M; Desaiah, D; El-Shafei, A; Faries, D; Feng, Q; Gado, M; Serebryakova, E; Treuer, T; Wu, S, 2014)	0.4
"Atomoxetine, a selective norepinephrine re-uptake inhibitor with a primary indication for attention dosed at 40 mg twice a day for 2 weeks, compared to placebo."	( Atomoxetine for attention deficits following traumatic brain injury: results from a randomized controlled trial. Brenner, LA; Cusick, C; Gerber, D; Harrison-Felix, C; Morey, CE; Pretz, CR; Ripley, DL; Wesnes, K, 2014)	0.4
"Young male spontaneously hypertensive rats (SHR), animal models of ADHD, were randomly divided into four groups according to the daily dosage of atomoxetine and treated for 21 consecutive days."	( Effect of atomoxetine on hyperactivity in an animal model of attention-deficit/hyperactivity disorder (ADHD). Bahn, GH; Han, J; Hong, M; Kim, CJ; Lee, YJ; Moon, SJ, 2014)	0.4
" Patterns of medication selection and dosing were compared with CMAP guidelines."	( Treatment receipt and outcomes from a clinic employing the attention-deficit/hyperactivity disorder treatment guideline of the children's medication algorithm project. McLennan, JD; Vallerand, IA; Wagner, DJ, 2014)	0.4
" Differences in pharmacokinetic parameters as well as clinical treatment outcomes across CYP2D6 genotype groups have resulted in dosing recommendations within the product label, but clinical studies supporting the use of genotype guided dosing are currently lacking."	( Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. Bishop, JR; Brown, JT, 2015)	0.42
"The aim was to investigate the dosing patterns of atomoxetine monotherapy in adult patients with attention-deficit/hyperactivity disorder (ADHD) in a retrospective analysis."	( Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder. Alatorre, C; Clemow, DB; Farr, AM; Kabul, S; Montejano, LB, 2015)	0.42
" After a 30-day titration period, dosing patterns of atomoxetine monotherapy were analyzed in the 12 months following initiation."	( Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder. Alatorre, C; Clemow, DB; Farr, AM; Kabul, S; Montejano, LB, 2015)	0.42
" The suboptimal dosing cohort included significantly more females (54% vs."	( Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder. Alatorre, C; Clemow, DB; Farr, AM; Kabul, S; Montejano, LB, 2015)	0.42
"Adult patients with ADHD receiving atomoxetine therapy in a real-world setting are often dosed suboptimally."	( Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder. Alatorre, C; Clemow, DB; Farr, AM; Kabul, S; Montejano, LB, 2015)	0.42
"For psychostimulants, a marked individual variability in the dose-response relationship and large differences in plasma concentrations after similar doses are known."	( Quantification of Methylphenidate, Dexamphetamine, and Atomoxetine in Human Serum and Oral Fluid by HPLC With Fluorescence Detection. Dörfelt, A; Haen, E; Stegmann, B, 2016)	0.43
" This has implications for physician atomoxetine dosing and efficacy assessment, patient education and outcomes, and for clinical trial design and assessment of comparative efficacy with stimulant medications."	( Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. Bushe, CJ; Clemow, DB, 2015)	0.42
" These data support the need for individualized dosing strategies for more effective use of the medication."	( Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Abdel-Rahman, SM; Brown, JT; Gaedigk, A; Leeder, JS; Lin, YS; van Haandel, L, 2016)	0.43
" Lastly, dosage adjustments based on pharmacokinetic principles are discussed."	( Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. Li, GF; Markowitz, JS; Yu, G, 2016)	0.43
"Pooled placebo (n = 485) and atomoxetine (n = 518) patients, dosed 25, 40, 60, 80 (target dose), or 100 mg daily, were assessed."	( Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials. Buchanan, AS; Clemow, DB; Findling, RL; Sarkis, EH; Wietecha, LA; Young, JL, 2016)	0.43
" There was no correlation between plasma atomoxetine concentrations and the corrected QT interval (QTc), or between atomoxetine dosage and the QTc."	( Sex Differences in the Effect of Atomoxetine on the QT Interval in Adult Patients With Attention-Deficit Hyperactivity Disorder. Egawa, J; Hayashi, T; Inoue, Y; Orime, N; Someya, T; Sugai, T; Sugimoto, A; Suzuki, Y; Tajiri, M, 2017)	0.46
" An understanding of CYP450 metabolism and drug interaction as well as metabolism phenotypes should inform prescribing and dosing psychotropic medications."	( Case report: Cytochrome P450 implications for comorbid ADHD and OCD pharmacotherapy. Hogan, MK; Rao, NP, 2017)	0.46
" In one study, tics limited further dosage increases of methylphenidate."	( Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Osland, ST; Pringsheim, T; Steeves, TD, 2018)	0.48
" This study was designed to predict the doses of trazodone to guide dosing in a clinical trial for pediatric insomnia using physiologically-based pharmacokinetic (PBPK) modeling."	( Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone-Atomoxetine Interaction. Calisti, F; Chetty, M; Garofolo, F; Ke, AB; Oggianu, L; Petrucci, V; Picollo, R; Tongiani, S, 2020)	0.56
" Simple physiologically based pharmacokinetic (PBPK) models and compartment models were set up to account for drug monitoring results of 33 Japanese patients (6-15 years of age) to help establish the correct dosage for the evaluation of clinical outcomes."	( Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6. Nakano, A; Notsu, Y; Ota, M; Sasaki, T; Shimizu, M; Yamazaki, H; Yoshida, S, 2020)	0.56
" Studies using standardized dosing schemes for longer durations and evaluating sleep with objective measurements may clarify the differential effects of treatments on sleep among children with ADHD."	( Sleep habits of children diagnosed with attention/ deficit/ hyperactivity disorder and effects of treatment on sleep related parameters. Sarıgedik, E; Tufan, AE; Yektaş, Ç, 2020)	0.56
" ADHD medication fillings were at optimal dosage 91."	( Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort. Bérard, A; Boukhris, T; Lemelin, M; Sheehy, O; Zhao, JP, 2021)	0.62
" Human mesenchymal stem cells (hMSCs) were incubated with a therapeutic plasma dosage of modafinil, atomoxetine and guanfacine."	( Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration. Böker, KO; Di Fazio, P; Jäckle, K; Lehmann, W; Schilling, AF; Wagener, N; Weiser, L, 2022)	0.72
" This review aims to evaluate current evidence to characterize the dose-exposure relationship, establish clinically relevant metrics for systemic exposure to atomoxetine, define a therapeutic exposure range, and to provide a dose-adaptation strategy before implementing personalized dosing for atomoxetine in children with ADHD."	( Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence. Chen, F; Fang, WR; Fu, D; Guo, HL; Hu, YH; Liu, QQ; Wu, DD; Xu, J, 2023)	0.91
"Personalizing atomoxetine dosage may be even more complex than anticipated thus far, but elucidating the best way to tailor the non-stimulant to a patient's individual need will be achieved by combining two strategies: detailed research in linking the pharmacokinetics and pharmacodynamics in pediatric patients, and better understanding in nature and causes of ADHD, as well as environmental stressors."	( Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence. Chen, F; Fang, WR; Fu, D; Guo, HL; Hu, YH; Liu, QQ; Wu, DD; Xu, J, 2023)	0.91
"Ato-Trazo has the potential to become a useful drug combination, however, longer trials are needed to determine the best dosage and the subgroup of patients who may benefit most from this combination."	( Effects of atomoxetine plus a hypnotic on obstructive sleep apnea severity in patients with a moderately collapsible pharyngeal airway. Corser, B; Eves, E; Rucosky, G; Warren-McCormick, J, 2023)	0.91
" These findings suggest that pre-emptive CYP2D6/CYP2C19 genotyping should be performed to individualize atomoxetine dosing and prevent adverse effects."	( Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data. Bernard, JP; Molden, E; Smith, RL, 2023)	0.91
" It is important that future research addresses the current weaknesses in this area, which include small sample sizes, variability of selection criteria, variability of the type and dosage of supplementation, and short follow-up times."	( Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Gillies, D; Leach, MJ; Perez Algorta, G, 2023)	0.91

Role	Description
antidepressant	Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
adrenergic uptake inhibitor	Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
hydrochloride	A salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
glp-1 receptor, partial	Homo sapiens (human)	Potency	5.0119	0.0184	6.8060	14.1254	AID624417
TDP1 protein	Homo sapiens (human)	Potency	19.1804	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	17.7966	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	33.4915	0.0002	21.2231	8,912.5098	AID1259243; AID1259247
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	11.8832	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	33.4915	0.0010	22.6508	76.6163	AID1224838
progesterone receptor	Homo sapiens (human)	Potency	26.6032	0.0004	17.9460	75.1148	AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	21.8761	0.0123	7.9835	43.2770	AID1645841
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	29.8493	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	26.6982	0.0015	30.6073	15,848.9004	AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
cytochrome P450 2D6	Homo sapiens (human)	Potency	2.4545	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	33.4889	0.0010	24.5048	61.6448	AID743212
IDH1	Homo sapiens (human)	Potency	18.3564	0.0052	10.8652	35.4813	AID686970
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	33.4915	0.0016	28.0151	77.1139	AID1259385
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	22.1639	0.0578	21.1097	61.2679	AID1159526; AID1159528
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	21.6403	0.0003	23.4451	159.6830	AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	37.5751	0.0006	27.2152	1,122.0200	AID743202
geminin	Homo sapiens (human)	Potency	0.7943	0.0046	11.3741	33.4983	AID624297
Cellular tumor antigen p53	Homo sapiens (human)	Potency	10.5909	0.0023	19.5956	74.0614	AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0008	1.5416	20.0000	AID1745860
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
monoamine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
chemical synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to pain	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuron cellular homeostasis	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID187146	Binding affinity against 5-HT uptake site, using [3H]citalopram as radioligand in rat cortical membrane	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Iodinated tomoxetine derivatives as selective ligands for serotonin and norepinephrine uptake sites.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1912479	Inhibition of the Norepinephrine transporter (NET, SLC6A2) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay in HEK-293 JumpIN-SLC6A2 cells (PubChem AID: 174586	2021	Scientific reports, 06-10, Volume: 11, Issue:1	Label-free high-throughput screening assay for the identification of norepinephrine transporter (NET/SLC6A2) inhibitors.
AID1453444	Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells at 100 uM using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (0.38)	18.7374
1990's	14 (1.07)	18.2507
2000's	434 (33.08)	29.6817
2010's	684 (52.13)	24.3611
2020's	175 (13.34)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	306 (22.08%)	5.53%
Reviews	293 (21.14%)	6.00%
Case Studies	120 (8.66%)	4.05%
Observational	19 (1.37%)	0.25%
Other	648 (46.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (184)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Atomoxetine Treatment for ADHD and Marijuana Dependence [NCT00360269]	Phase 2	38 participants (Actual)	Interventional	2005-11-30	Completed
Efficacy of Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents and Young Adults With Substance Use Disorders (SUD) [NCT01207622]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to Poor enrollment)
Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study [NCT00368849]	Phase 2	20 participants (Actual)	Interventional	2005-11-30	Completed
Phase 2 Randomized Double-Blind Placebo-Controlled 4-Period Single-Dose Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to the Efficacy of AD109 in Obstructive Sleep Apnea [NCT04580394]	Phase 2	60 participants (Actual)	Interventional	2020-10-27	Completed
A Phase 2, Multicenter, Randomized, Double-blind, Active- and Placebo-controlled Trial of the Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder [NCT03324581]	Phase 2	239 participants (Actual)	Interventional	2017-11-09	Completed
TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study [NCT02879136]	Early Phase 1	42 participants (Anticipated)	Interventional	2016-12-31	Recruiting
[NCT03661788]	Phase 4	38 participants (Actual)	Interventional	2016-05-31	Completed
Cortical Excitability: Phenotype and Biomarker in ADHD Therapy [NCT01330693]	Phase 3	120 participants (Anticipated)	Interventional	2009-09-30	Active, not recruiting
A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 Weeks in Newly Diagnosed Children and Adolescents Outpatients With Attention-Deficit/Hyperactivity Disorder [NCT00191945]	Phase 3	151 participants (Actual)	Interventional	2005-05-31	Completed
Efficacy of Careful Medication and Tailored Case Management Follow up Treatment for Children With Attention Deficit Hyperactivity Disorder [NCT02142140]		326 participants (Anticipated)	Interventional	2012-12-31	Active, not recruiting
Evaluation of Atomoxetine and Oxybutynin for Obstructive Sleep Apnea in Children With Down Syndrome [NCT04115878]	Phase 2	22 participants (Actual)	Interventional	2020-10-21	Completed
Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT02430896]		600 participants (Anticipated)	Observational	2015-02-28	Recruiting
Effect of Atomoxetine and Oxybutynin on Phenotype Traits and OSA Severity [NCT02908529]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2016-09-30	Completed
A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST6 [NCT02500732]	Phase 2	57 participants (Actual)	Interventional	2015-07-31	Completed
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk [NCT03781765]	Phase 4	44 participants (Anticipated)	Interventional	2019-06-04	Recruiting
Study of Associated Gene Polymorphisms With Atomoxetine Response Prediction in ADHD Treatment [NCT01339286]	Phase 4	100 participants (Anticipated)	Interventional	2011-03-31	Recruiting
An Open-Label, Single- and Multi-Dose Study to Evaluate the Relationship Between the Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of Atomoxetine in CYP2D6 Extensive, Intermediate and Poor Metabolizers in Children With Attention Deficit/Hypera [NCT03154359]		51 participants (Actual)	Observational	2017-12-12	Completed
[NCT01130467]		150 participants (Anticipated)	Observational	2009-09-30	Recruiting
The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With Attention Deficit Hyperactivity Disorder: A Lipidomic Study [NCT03936491]		105 participants (Anticipated)	Interventional	2019-08-01	Not yet recruiting
Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis [NCT03091400]	Phase 2	11 participants (Actual)	Interventional	2017-03-16	Completed
A Gene by Medication Interaction to the Acute Effects of Alcohol [NCT01343628]	Phase 1	43 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Terminated due to lack of funding)
Atomoxetine Effects in Humans [NCT00607568]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2006-06-30	Completed
Pharmacological Treatment of ADHD in Young Children [NCT00254462]	Phase 4	93 participants (Actual)	Interventional	2005-10-01	Completed
The Reinforcing Mechanisms of Smoking in Adult ADHD [NCT00573859]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2006-09-30	Completed
Feasibility and Utility of Autonomic Correlates of Impulsivity in Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD): Extending Translational Research Skills [NCT00856063]	Phase 4	5 participants (Actual)	Interventional	2009-03-31	Completed
A Controlled Trial of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women [NCT00611533]		16 participants (Actual)	Interventional	2004-05-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD) [NCT00528697]	Phase 2	278 participants (Actual)	Interventional	2007-09-30	Completed
Enhancement of Post-stroke Neural Plasticity With Atomoxetine: a Pilot Study [NCT02788357]	Phase 2	12 participants (Actual)	Interventional	2006-11-30	Completed
Effect of Atomoxetine and DAW2022 on OSA Severity [NCT05350215]	Phase 1/Phase 2	18 participants (Anticipated)	Interventional	2022-06-01	Recruiting
Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy [NCT05550246]	Phase 1/Phase 2	22 participants (Anticipated)	Interventional	2022-05-05	Recruiting
Measuring and Predicting Response to Atomoxetine and Methylphenidate [NCT00183391]	Phase 4	232 participants (Actual)	Interventional	2005-07-31	Completed
A Randomized, Double-Blind Comparison of Atomoxetine Versus Placebo in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder [NCT00406354]	Phase 4	181 participants (Actual)	Interventional	2006-11-30	Completed
A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder [NCT00568685]	Phase 3	153 participants (Actual)	Interventional	2007-11-30	Completed
A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder [NCT00380692]	Phase 4	97 participants (Actual)	Interventional	2006-10-31	Completed
A Pilot Study of Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified [NCT00181766]	Phase 4	45 participants (Actual)	Interventional	2003-12-31	Completed
Driving Ability in Adults With ADHD Before and After 10-weeks of Treatment With 40-80mg Atomoxetine vs. Untreated Adults With ADHD [NCT00938743]	Phase 4	50 participants (Anticipated)	Interventional	2008-01-31	Completed
Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome [NCT05933603]	Phase 2	36 participants (Anticipated)	Interventional	2023-08-01	Recruiting
Orthostatic Intolerance After Bariatric Surgery [NCT03808740]	Phase 1	16 participants (Actual)	Interventional	2018-07-01	Completed
Effects of Atomoxetine Treatment in Humans [NCT00611936]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2006-06-30	Completed
Atomoxetine and Cerebrovascular Outcomes in Adults [NCT00634439]		72,000 participants (Anticipated)	Observational	2008-01-31	Completed
Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine, a Post-authorization Safety Study [NCT04132557]		430,000 participants (Actual)	Observational	2019-10-09	Completed
A Double-Blind Study of Atomoxetine Hydrochloride Versus Placebo for the Treatment of ADHD in Young Adults With an Assessment of Associated Functional Outcomes [NCT00510276]	Phase 4	445 participants (Actual)	Interventional	2007-08-31	Completed
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial [NCT00617201]	Phase 2	50 participants (Actual)	Interventional	2007-07-31	Completed
Treatment of Orthostatic Intolerance [NCT00262470]	Phase 1/Phase 2	150 participants (Anticipated)	Interventional	1997-04-30	Active, not recruiting
A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia [NCT00607919]	Phase 4	209 participants (Actual)	Interventional	2008-03-31	Completed
Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Atomoxetine on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype [NCT00548327]	Phase 2	11 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to The scientific director decided to terminate: low priority study with slow accrual)
Therapeutic Drug Monitoring (TDM) in Child & Adolescent Psychiatry [NCT01057329]		200 participants (Actual)	Observational	2010-01-31	Completed
An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse. [NCT00687609]	Phase 4	7 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to The study was discontinued early, owing to difficulties in recruiting the target sample after seven patients had been recruited.)
LY139603 Bioequivalence Study Comparing Atomoxetine Oral Solution and Capsule Formulation in Healthy Adult Male Japanese Subjects [NCT01177943]	Phase 1	42 participants (Actual)	Interventional	2010-08-31	Completed
Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study) [NCT01127646]	Phase 4	23 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Due to lack of availability of study participants to accommodate the study design)
Near-infrared Spectroscopy Neurofeedback as a Treatment for Children With Attention Deficit Hyperactivity Disorder [NCT04065906]		90 participants (Anticipated)	Interventional	2019-01-15	Recruiting
A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel Group Study to Assess the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disor [NCT01106430]	Phase 3	267 participants (Actual)	Interventional	2010-06-28	Completed
Role of Coenzyme Q in Treatment of Attention Deficit Hyperactivity Disorder in Children [NCT04216186]	Phase 3	40 participants (Anticipated)	Interventional	2018-11-01	Recruiting
Effects of Strattera and Behavior Therapy on the School and Home Functioning of Elementary School Children With Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT00918567]	Phase 4	56 participants (Actual)	Interventional	2007-01-31	Completed
Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine [NCT04565288]	Phase 2	42 participants (Actual)	Interventional	2021-05-06	Active, not recruiting
Randomized Double-Blind 2-Period Multiple Dose Crossover Study to Evaluate the Efficacy and Safety of AD113 vs Atomoxetine in OSA Patients With Hypertension [NCT04905979]	Phase 2	21 participants (Actual)	Interventional	2021-07-31	Completed
A Pharmacotherapy Study: A Dose Response Effect of Atomoxetine on Alcohol-elicited Craving and Sensitivity to the Acute Effects of Alcohol [NCT01408589]	Phase 1	86 participants (Actual)	Interventional	2005-06-30	Terminated
A Randomized, Double Blind Comparison of the Effects of Atomoxetine Versus Placebo on Neuropsychological Outcomes Across the Day in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) by Use of a Computer Based Continuous Performance Test (cb CP [NCT00546910]	Phase 4	125 participants (Actual)	Interventional	2007-10-31	Completed
Comprehensive Pathophysiological Study Based on the Core Neurocognitive Deficits and Development of Biological Markers of Treatment Response in Attention Deficit Hyperactivity Disorder [NCT02623114]	Phase 4	400 participants (Anticipated)	Interventional	2012-05-31	Recruiting
Open-Label 4-Period Dose-Escalation Safety and Efficacy Study of AD313 in Participants With Obstructive Sleep Apnea [NCT05101122]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2021-10-19	Completed
A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning Compared With Fast Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hypera [NCT00760747]	Phase 4	112 participants (Actual)	Interventional	2008-09-30	Completed
The Relative Efficacy of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) Versus Medication Only and the Combination of the Two: A Pilot Study [NCT02788851]		70 participants (Anticipated)	Interventional	2016-04-30	Active, not recruiting
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine [NCT00780650]	Early Phase 1	56 participants (Actual)	Interventional	2009-05-31	Completed
Randomized Control Study of Concerta and Strattera on the Improvement of Executive Function in Attention Deficit Hyperactivity Disorder Children [NCT01065259]	Phase 4	262 participants (Actual)	Interventional	2008-04-30	Completed
Double Blind Placebo Controlled Parallel Group Comparison of Atomoxetine (Strattera) for Generalized Social Anxiety Disorder (GSAD) [NCT00260533]	Phase 2/Phase 3	27 participants (Actual)	Interventional	2005-11-30	Completed
Bariatric Surgery and Pharmacokinetics of Atomoxetine: BAR-MEDS Atomoxetine [NCT03460210]		12 participants (Anticipated)	Observational	2016-11-02	Recruiting
Treating Residual OSA With Endotype-directed Pharmacotherapy (Aim 3) [NCT05293600]	Phase 1/Phase 2	70 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
A Pilot Study of Concerta Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified [NCT00181740]	Phase 4	30 participants	Interventional	2003-12-31	Completed
Treatment Adherence and Compliance in Children and Adolescents on ADHD Medication and Emotional Expression in Clinical Practice [NCT00540826]		518 participants (Actual)	Observational	2007-11-30	Completed
A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning Using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder in Treatment-Naïve Children and Adolescent [NCT00447278]	Phase 3	399 participants (Actual)	Interventional	2007-03-31	Completed
Targeted Pharmacologic Interventions for Autism: A Double-Blind, Placebo-Controlled Trial of Atomoxetine in Children and Adolescents With Autism [NCT00498173]	Phase 3	60 participants (Actual)	Interventional	2007-07-31	Completed
An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder With or Without Comorbid Conditions [NCT00320528]	Phase 3	269 participants (Actual)	Interventional	2006-04-30	Completed
Correlation of Phenotype, Genotype and Clinical Efficacy/Toxicity of Clozapine Augmented by Atomoxetine for Treatment Refractory Schizophrenia (CAPG Study) [NCT00216281]	Phase 3	126 participants (Actual)	Interventional	2005-09-30	Terminated
A Randomized, Parallel Group, Double Blind, Placebo Controlled, Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder [NCT00222794]	Phase 4	66 participants	Interventional	2003-11-30	Completed
Evaluation and Treatment of Autonomic Failure. [NCT00223691]	Phase 1	389 participants (Actual)	Interventional	2002-03-31	Completed
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms [NCT04782830]		29 participants (Anticipated)	Interventional	2021-02-05	Recruiting
A Study to Assess the Cardiovascular, Cognitive and Subjective Effects of Atomoxetine in Combination With Intravenous Methamphetamine [NCT02014064]	Phase 1	41 participants (Actual)	Interventional	2009-08-31	Completed
[NCT02046551]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2014-04-30	Withdrawn(stopped due to funding lost)
Phase III Multicenter, Randomized, Double-Blind Placebo-Controlled Outpatient Study of Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disor [NCT00386581]	Phase 3	105 participants (Actual)	Interventional	2004-07-31	Completed
Phase 2, Randomized, Double-Blind, Parallel-Group, Four Week, Efficacy And Safety Trial Of [S,S]-Reboxetine (PNU-165442g) And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder. [NCT00562055]	Phase 2	0 participants (Actual)	Interventional	2007-11-30	Withdrawn(stopped due to This study was withdrawn due to business reasons.)
Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride [NCT00471354]	Phase 4	228 participants (Actual)	Interventional	2007-04-30	Completed
An Italian Randomised, Double-blind Placebo Controlled Study of the Efficacy of Atomoxetine Hydrochloride in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder [NCT00192023]	Phase 3	139 participants (Actual)	Interventional	2004-10-31	Completed
A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder. [NCT00191906]	Phase 4	121 participants (Actual)	Interventional	2005-04-30	Completed
A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder: With a Secondary Examination of Impact of Treatment on Family Functioning [NCT00190775]	Phase 4	502 participants (Actual)	Interventional	2004-09-30	Completed
Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders: a Randomized Controlled Clinical Trial for the Treatment of Central Sensitization [NCT01601912]		59 participants (Actual)	Observational	2013-02-28	Completed
Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan: A Retrospective Cohort Study of Label Compliance [NCT04113551]		17,418 participants (Actual)	Observational	2019-10-01	Completed
Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine Treatment [NCT00716274]	Phase 4	110 participants (Actual)	Interventional	2008-09-30	Completed
A Randomized, Placebo-controlled Trial of Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder (SUD) [NCT00399763]		70 participants (Actual)	Interventional	2005-09-30	Completed
An Open-Label Pilot Study for Atomoxetine in Adult Subjects With Attention Deficit/Hyperactivity Disorder [NCT00530335]	Phase 2	45 participants (Actual)	Interventional	2007-09-30	Completed
Atomoxetine, Placebo and Parent Management Training in Autism [NCT00844753]	Phase 4	128 participants (Actual)	Interventional	2008-10-31	Completed
Long-Term, Open-Label Safety and Efficacy Study of Atomoxetine Hydrochloride in Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT00969618]	Phase 3	211 participants (Actual)	Interventional	2009-11-30	Completed
A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT00962104]	Phase 3	391 participants (Actual)	Interventional	2009-08-31	Completed
A Phase IIIb Open-Label Trial of Atomoxetine Hydrochloride to Evaluate Academic Outcome in Children Ages 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder [NCT00191880]	Phase 3	100 participants	Interventional	2004-05-31	Completed
A Pilot Trial of Atomoxetine to Enhance Motivational Interviewing Therapy for the Treatment of Cannabis Dependence [NCT00167297]	Phase 2	16 participants (Actual)	Interventional	2004-11-30	Completed
[NCT00089869]	Phase 1/Phase 2	0 participants	Interventional		Completed
A Multi-center Randomized Parallel Group Study Evaluating Treatment Outcomes of Concerta (Extended Release Methylphenidate) and Strattera (Atomoxetine) in Children With Attention-deficit/Hyperactivity Disorder [NCT00866996]	Phase 4	1,323 participants (Actual)	Interventional		Completed
Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications [NCT00697138]	Phase 1	46 participants (Actual)	Interventional	2006-06-30	Completed
An Open-Label Pilot Study of Atomoxetine Hydrochloride to Evaluate Neuropsychological Function in Children Ages 6 to 10 Years With Attention-Deficit/Hyperactivity Disorder. [NCT00216918]	Phase 4	40 participants	Interventional	2005-09-30	Completed
Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) [NCT00218322]	Phase 4	108 participants (Anticipated)	Interventional	2004-09-30	Completed
A Double-Blind Study of Functional Outcomes With Atomoxetine-Hydrochloride and Placebo in Adult Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder [NCT00190931]	Phase 4	400 participants	Interventional	2003-11-30	Completed
Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer's Disease [NCT00191009]	Phase 2/Phase 3	124 participants	Interventional	2003-10-31	Completed
Open-Label Treatment With Atomoxetine Hydrochloride in Child and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia [NCT00191048]	Phase 4	105 participants	Interventional	2003-10-31	Completed
An Open-Label Study on Effectiveness and Tolerability of Atomoxetine as Perceived by Patients, Parents, and Physicians in Children With Attention-Deficit/Hyperactivity Disorder in Germany [NCT00191516]	Phase 3	257 participants	Interventional	2004-10-31	Completed
A 3 Month Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder; Symptomatic and Functional Outcomes. [NCT00191633]	Phase 4	200 participants	Interventional	2005-04-30	Completed
Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia [NCT01863251]	Phase 2	90 participants (Actual)	Interventional	2013-05-31	Completed
Naturalistic Study of ADHD Medication and Predictors of Treatment Outcome [NCT02136147]		632 participants (Actual)	Observational [Patient Registry]	2015-06-30	Completed
A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With ADDERALL XR and STRATTERA Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With Attention Deficit Hyperactivity Disorder (ADHD [NCT00557960]	Phase 3	36 participants (Actual)	Interventional	2004-02-25	Completed
Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial [NCT00218543]	Phase 2	20 participants (Actual)	Interventional	2004-06-30	Completed
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia [NCT00488163]	Phase 4	20 participants (Actual)	Interventional	2005-01-31	Completed
Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With Attention-Deficit/Hyperactivity Disorder [NCT00485459]	Phase 3	106 participants (Actual)	Interventional	2004-02-29	Completed
A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented With Either Extended-Release Methylphenidate Hydrochloride (Concerta-TM) or Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Not Responded to Sti [NCT00485550]	Phase 3	14 participants (Actual)	Interventional	2004-01-31	Completed
An Open-Label, Dose Titration Safety Study of Atomoxetine Hydrochloride in Outpatient Japanese Children With Attention-Deficit/Hyperactivity Disorder [NCT00485628]	Phase 2	37 participants (Actual)	Interventional	2003-04-30	Completed
Noradrenergic Augmentation of SSRI Therapy in Patients With Depression Unresponsive or Incompletely Responsive to SSRI Monotherapy [NCT00485862]	Phase 4	214 participants (Actual)	Interventional	2003-06-30	Completed
A Randomized, Double-Blind, Parallel-Group, Analog Classroom Study, Evaluating ADDERALL XR Versus STRATTERA, Dosed Once Daily, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) [NCT00506727]	Phase 4	215 participants (Actual)	Interventional	2003-08-05	Completed
Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea [NCT05944965]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2023-10-22	Not yet recruiting
A Novel Pharmacological Therapy for Obstructive Sleep Apnea [NCT03919955]	Phase 2	75 participants (Anticipated)	Interventional	2019-09-03	Recruiting
Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison [NCT00356070]		40 participants	Interventional	2006-01-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT00429091]	Phase 2	243 participants (Actual)	Interventional	2007-01-31	Completed
Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations: a Randomized, Double-Blind Study [NCT00485407]	Phase 3	377 participants (Actual)	Interventional	2003-07-31	Completed
An Open-Label, Multicenter, Pilot Study of the Safety and Efficacy of Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT00485875]	Phase 4	62 participants (Actual)	Interventional	2004-06-30	Completed
Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia [NCT00161031]		30 participants (Anticipated)	Interventional	2004-04-30	Completed
Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment [NCT00142961]	Phase 2	2 participants (Actual)	Interventional	2005-10-31	Completed
Efficacy of Atomoxetine in Adults With ADHD and Substance Abuse Disorder Being Treated in a Residential Treatment Facility [NCT00953862]		18 participants (Actual)	Interventional	2005-07-31	Completed
Efficacy of Atomoxetine Therapy Versus Placebo For Ameliorating Cognitive Late Effects Among Survivors of Childhood Cancers [NCT00255138]	Phase 3	0 participants (Actual)	Interventional	2005-11-30	Withdrawn
A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder [NCT00191295]	Phase 2/Phase 3	240 participants	Interventional	2005-02-28	Completed
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months); With a Brief Evaluation of Executive Cognition [NCT00190736]	Phase 4	440 participants	Interventional	2004-09-30	Completed
The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia [NCT00566371]	Phase 4	36 participants (Anticipated)	Interventional	2005-06-30	Completed
Reading ICARD: Interventions for Children With Attention and Reading Disorders [NCT01133847]	Phase 4	222 participants (Actual)	Interventional	2010-11-30	Completed
An Open Label Pilot Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behavior Problems in Children and Adolescents With Autistic Spectrum Disorders [NCT00485849]	Phase 4	12 participants (Actual)	Interventional	2004-02-29	Completed
A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate Hydrochloride in Pediatric Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder [NCT00486083]	Phase 3	330 participants (Actual)	Interventional	2003-12-31	Completed
Evaluation of Continuous Symptom Treatment of ADHD: A Placebo-Controlled Double-Blind Assessment of Morning-Dosed or Evening-Dosed Strattera [NCT00486122]	Phase 4	282 participants (Actual)	Interventional	2003-09-30	Completed
A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hy [NCT01244490]	Phase 3	338 participants (Actual)	Interventional	2011-01-17	Completed
Psychopharmacology of Adolescents With AUD and ADHD [NCT00029614]	Phase 2	24 participants (Anticipated)	Interventional	2006-05-31	Completed
Eight-Week, Double-Blind, 3-Arm Parallel, Placebo-Controlled, Randomized Efficacy And Safety Trial Of Atomoxetine, Atomoxetine Plus Buspirone, And Placebo In Adults With Attention Deficit Hyperactivity Disorder [NCT00174226]	Phase 2	241 participants (Actual)	Interventional	2004-11-30	Completed
A Pilot Study of Strattera Treatment in Children With Attention-Deficit/Hyperactivity Disorder Who Have Poor Response to Stimulant Therapy [NCT00181948]	Phase 4	30 participants (Anticipated)	Interventional	2004-09-30	Completed
Phase IV Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder [NCT00190879]	Phase 4	440 participants	Interventional	2005-06-30	Completed
Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial [NCT00190957]	Phase 4	140 participants	Interventional	2004-08-31	Completed
Maintenance of Benefit After 8-Week and 52-Week Treatment With Atomoxetine Hydrochloride in Adolescents With ADHD [NCT00191035]	Phase 4	520 participants	Interventional	2004-03-31	Completed
A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and Adolescents [NCT00191542]	Phase 3	100 participants	Interventional	2005-03-31	Completed
A Randomised, Controlled, Open-Label Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents [NCT00191659]	Phase 3	200 participants	Interventional	2004-06-30	Completed
A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder [NCT00191698]	Phase 3	226 participants (Actual)	Interventional	2003-12-31	Completed
An Open-Label Study on Effectiveness and Tolerability of Atomoxetine, as Perceived by Patients, Parents, and Physicians in Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany [NCT00191737]	Phase 3	147 participants	Interventional	2004-10-31	Completed
Long-Term Extension, Open-Label Study of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder [NCT00191386]	Phase 3	228 participants (Actual)	Interventional	2005-05-31	Completed
Long-Term, Open Label Safety Study of Atomoxetine Hydrochloride in Patients, 6 Years and Older With Attention-Deficit/Hyperactivity Disorder [NCT00190684]	Phase 3	1,553 participants (Actual)	Interventional	2000-08-31	Completed
The Effect of a Once Daily Evening Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents [NCT00252278]	Phase 4	36 participants	Interventional	2005-11-30	Recruiting
Phase 1, Double-Blind, Placebo-Controlled Multiple Dose Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine [NCT00265265]	Phase 1	16 participants	Interventional	2005-08-31	Completed
A Study of the Efficacy of Atomoxetine in Treating the Inattention, Impulsivity and Hyperactivity in Children With Fetal Alcohol Syndrome or Effects [NCT00417794]	Phase 1	38 participants (Actual)	Interventional	2005-08-31	Completed
Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia [NCT00299234]	Phase 4	1 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Insufficient number of interested potentital subjects)
Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients [NCT00327834]	Phase 4	0 participants	Interventional	2006-05-31	Completed
Effects of Atomoxetine on Cognitive Function in Schizophrenia [NCT00420498]	Phase 2	12 participants (Actual)	Interventional	2005-08-31	Completed
Prospective Follow-Up Observational Study to Examine the Progression of ADHD Drug Treatment and to Analyze Associated Factors [NCT01624649]		289 participants (Actual)	Observational	2012-02-29	Completed
Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline - a PET Study in Healthy Human Subjects [NCT01435213]	Phase 1	10 participants (Actual)	Interventional	2011-09-30	Completed
A Study to Assess the Cardiovascular, Cognitive and Subjective Effects of Atomoxetine in Combination With Intravenous Methamphetamine [NCT01019707]	Phase 1	6 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to End in funding)
An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-deficit/Hyperactivity Disorder [NCT00636818]	Phase 2	45 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder [NCT00880217]	Phase 2	430 participants (Actual)	Interventional	2009-05-31	Completed
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach [NCT01678209]	Phase 4	127 participants (Actual)	Interventional	2012-10-31	Completed
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With DESR Traits: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial [NCT01399827]	Phase 2	2 participants (Actual)	Interventional	2012-02-29	Completed
Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study [NCT00286949]		12 participants (Actual)	Interventional	2005-01-06	Completed
[NCT01557569]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2012-04-30	Completed
Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study [NCT01340885]	Phase 4	9 participants (Actual)	Interventional	2011-01-31	Completed
Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study [NCT02287038]	Phase 4	44 participants (Actual)	Interventional	2014-10-15	Completed
A Randomized, Prospective, Placebo-Controlled, Crossover Study of Atomoxetine in the Prevention of Vasovagal Syncope (POST7) [NCT05159687]	Phase 3	180 participants (Anticipated)	Interventional	2022-06-01	Recruiting
Dialectical Behavioral Therapy Skills for Impulsive Aggression in Children Diagnosed With Attention Deficit Hyperactivity Disorder at Alexandria University Hospitals [NCT05351944]		62 participants (Actual)	Interventional	2023-05-07	Active, not recruiting
Depression Diagnosis and Treatment in Parkinson Disease [NCT00304161]	Phase 4	55 participants (Actual)	Interventional	2004-07-31	Completed
Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline - a PET Study in Healthy Human Subjects [NCT01794975]	Phase 1	8 participants (Actual)	Interventional	2012-08-31	Completed
Atomoxetine, Diurnal Profiles of Cortisol and α-amylase, Possible Biological Markers of Treatment Success [NCT03075579]		50 participants (Anticipated)	Observational	2016-12-01	Recruiting
Equine-Assisted Activities and Therapy for Treating Children With Attention-Deficit/Hyperactivity Disorder [NCT02482649]		46 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Maintenance of Response After Open-Label Treatment With Atomoxetine Hydrochloride in Adult Outpatients With Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study [NCT00700427]	Phase 3	2,017 participants (Actual)	Interventional	2008-06-30	Completed
A Pilot Study to Evaluate the Effects of Atomoxetine on Impulsivity in Patients With Tourette's Syndrome [NCT04354103]	Phase 2	20 participants (Anticipated)	Interventional	2022-05-31	Recruiting
A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfac [NCT04085172]	Phase 4	288 participants (Anticipated)	Interventional	2019-09-18	Recruiting
Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog) [NCT01738191]	Phase 2	30 participants (Actual)	Interventional	2012-11-30	Completed
Atomoxetine Treatment for Opioid Maintained Cocaine Users [NCT01802515]		14 participants (Actual)	Interventional	2012-12-31	Terminated(stopped due to No funding stopped recruitment march 2014 with only 14 enrolled)
Efficacy and Safety/Tolerability of OROS MPH (Concerta) Plus Atomoxetine (ATMX) in Children and Adolescents (Age 6-17) With Attention Deficit Hyperactivity Disorder (ADHD) [NCT00585910]	Phase 4	94 participants (Actual)	Interventional	2004-01-31	Completed
Strattera(Atomoxetine) for the Treatment of Attention Disorders in Individuals With Traumatic Brain Injury [NCT00702364]		60 participants (Actual)	Interventional	2008-01-31	Completed
An Open-label Study of the Long Term Tolerability and Safety of Atomoxetine in Treating the Inattention, Impulsivity and Hyperactivity in Children With Fetal-Alcohol Syndrome or Effects. [NCT00418262]	Phase 3	27 participants (Actual)	Interventional	2005-08-31	Completed
Cognitive Effects of Atomoxetine in Humans: Genetic Moderators [NCT01498549]		35 participants (Actual)	Interventional	2011-12-31	Completed
Cognitive Treatments in Schizophrenia [NCT00628394]	Phase 4	119 participants (Actual)	Interventional	2003-09-30	Completed
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine [NCT04445688]	Phase 2	62 participants (Actual)	Interventional	2020-07-15	Completed
Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12 [NCT02784535]	Phase 2	48 participants (Actual)	Interventional	2016-08-29	Completed
Efficacy and Safety of Midodrine and Atomoxetine Treatment in Patients With Neurogenic Orthostatic Hypotension : A Prospective Randomized Study [NCT03350659]	Phase 4	50 participants (Actual)	Interventional	2018-01-01	Completed
A 6 Month, Phase II Randomized, Double-Blind, Placebo Controlled, Flexible Dosing, Crossover Trial of Atomoxetine in Subjects With Mild Cognitive Impairment. [NCT01522404]	Phase 2	39 participants (Actual)	Interventional	2012-03-31	Completed
Effects of Atomoxetine and Oros-mph on Executive Functions in Patients With Combined Type Attention Deficit Hyperactivity Disorder [NCT02352051]	Phase 4	43 participants (Actual)	Interventional	2014-02-28	Completed
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea [NCT05071612]	Phase 2	294 participants (Actual)	Interventional	2021-11-29	Completed
Multimodal Magnetic Resonance Imaging Study on the Neural Mechanisms of Remission in Children With ADHD Treated With Methylphenidate or Atomoxetine [NCT05229627]		250 participants (Anticipated)	Observational	2016-01-31	Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00181766 (2) [back to overview]	The Adult AISRS
NCT00181766 (2) [back to overview]	ADHD-Clinical Global Impression
NCT00183391 (16) [back to overview]	Tics: Total Motor
NCT00183391 (16) [back to overview]	Continuous Performance Test (CPT)
NCT00183391 (16) [back to overview]	Children's Sleep Questionnaire
NCT00183391 (16) [back to overview]	Clinical Global Impressions (CGI)- Severity
NCT00183391 (16) [back to overview]	Child Conflict Index (CCI)
NCT00183391 (16) [back to overview]	Assessment of Affective Range (AAR)
NCT00183391 (16) [back to overview]	ADHD-RS Total Score
NCT00183391 (16) [back to overview]	ADHD-RS Inattention
NCT00183391 (16) [back to overview]	ADHD - H/I
NCT00183391 (16) [back to overview]	Tics: Total Impairment
NCT00183391 (16) [back to overview]	Vital Signs - Systolic Blood Pressure
NCT00183391 (16) [back to overview]	Vital Signs - Pulse
NCT00183391 (16) [back to overview]	Vital Signs - Diastolic Blood Pressure
NCT00183391 (16) [back to overview]	Treatment Preference Survey
NCT00183391 (16) [back to overview]	Tics: Total Phonic
NCT00183391 (16) [back to overview]	Social Skills Rating Scale (SSRS)- Parent Version
NCT00190684 (15) [back to overview]	Change From Baseline to 5 Year Endpoint in Weight, Height, and Body Mass Index (BMI) Percentile Stratified by Baseline Quartile
NCT00190684 (15) [back to overview]	Change From Baseline to 5 Year Endpoint in Electrocardiogram (ECG)
NCT00190684 (15) [back to overview]	Change From Baseline to 5 Year Endpoint in Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S) Subscale Scores
NCT00190684 (15) [back to overview]	Change From Baseline to 5 Year Endpoint in Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity (CGI-ADHD-S) Score
NCT00190684 (15) [back to overview]	Change From Baseline to 5 Year Endpoint in Heart Rate
NCT00190684 (15) [back to overview]	Change From Baseline to 5 Year Endpoint in Height
NCT00190684 (15) [back to overview]	Change From Baseline to 5 Year Endpoint in Pulse
NCT00190684 (15) [back to overview]	Change From Baseline to 5 Year Endpoint in BP
NCT00190684 (15) [back to overview]	Categorical Changes in Vital Signs (Blood Pressure [BP], Pulse, Weight, Temperature) During the Study
NCT00190684 (15) [back to overview]	Change From Baseline to 5 Year Endpoint in Body Weight
NCT00190684 (15) [back to overview]	Change From Baseline to 5 Year Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score and Subscale Scores
NCT00190684 (15) [back to overview]	Number of Patients Meeting CPMP Categorical QTc Interval Criteria Part II (Interpretation at Baseline and Endpoint)
NCT00190684 (15) [back to overview]	Number of Patients Meeting Committee for Proprietary Medicinal Products (CPMP) Categorical QTc Interval Criteria Part I (Numerical Increase)
NCT00190684 (15) [back to overview]	Number of Participants With Abnormal Laboratory Analytes During the Study
NCT00190684 (15) [back to overview]	Number of Participants in Each Tanner Stage (Pubic Hair) by Age Group
NCT00190775 (31) [back to overview]	Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Parent Domains
NCT00190775 (31) [back to overview]	Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Total Stress and Life Stress
NCT00190775 (31) [back to overview]	Change From Baseline to 12 and 24 Weeks in the Montgomery-Asberg Depression Rating Scale Total Score (MADRS)
NCT00190775 (31) [back to overview]	Change From Baseline to 12 and 24 Weeks in the Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale Total and Subscale Scores
NCT00190775 (31) [back to overview]	Change From Baseline to 1 Week of Titration in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptoms Score
NCT00190775 (31) [back to overview]	Mean Change From Baseline to 24 Weeks in the Child Disruptive Behavior Rating Scale (CDBRS) Parent Form Oppositional Defiant Disorder (ODD) and Conduct Disorder Flags
NCT00190775 (31) [back to overview]	Change From Baseline to 8 Weeks in the Dyadic Adjustment Scale (DAS) - Participant
NCT00190775 (31) [back to overview]	Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Child Domains
NCT00190775 (31) [back to overview]	Change From Baseline to 12 Weeks in the Alabama Parenting Questionnaire (APQ) Parent Form
NCT00190775 (31) [back to overview]	Change From Baseline to After a 2-Week Titration Period Beginning at Week 24 and Ending at Week 26 in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores: Dosing Titration Strategy After Placebo
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Parent Domains
NCT00190775 (31) [back to overview]	Change From Baseline to 8 Weeks in the Dyadic Adjustment Scale (DAS) - Spouse/Significant Other
NCT00190775 (31) [back to overview]	Change From Baseline to 12 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptoms Score
NCT00190775 (31) [back to overview]	Change From Baseline to 8 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Participant
NCT00190775 (31) [back to overview]	Change From Baseline to 8 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Spouse/Significant Other
NCT00190775 (31) [back to overview]	Mean Change From Baseline to 24 Weeks in the Child Disruptive Behavior Rating Scale (CDBRS) Parent Form
NCT00190775 (31) [back to overview]	Change From Baseline to 8 Weeks in the Parenting Sense of Competence (PSOC) Scale
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Child Domains
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Dyadic Adjustment Scale (DAS) - Participant
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Total Stress and Life Stress
NCT00190775 (31) [back to overview]	Change From Baseline to 8 and 24 Weeks in the Clinical Global Improvement Attention Deficit Hyperactivity Disorder Severity (CGI-ADHD-S)
NCT00190775 (31) [back to overview]	Change From Baseline to 2 Weeks of Titration in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Alabama Parenting Questionnaire (APQ) Child Form
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Alabama Parenting Questionnaire (APQ) Parent Form
NCT00190775 (31) [back to overview]	Change From Baseline to 12 and 24 Weeks in the State-Trait Anxiety Inventories (STAI)
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Dyadic Adjustment Scale (DAS) - Spouse/Significant Other
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Participant
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Spouse/Significant Other
NCT00190775 (31) [back to overview]	Change From Baseline to 24 Weeks in the Parenting Sense of Competence (PSOC) Scale
NCT00190775 (31) [back to overview]	Change From Baseline to 12 Weeks in the Alabama Parenting Questionnaire (APQ) Child Form
NCT00191386 (4) [back to overview]	Change From Baseline at Various Timepoints in Attention Deficit Hyperactivity Disorder Rating Scale-IV-Translated in Japanese Parent Version: Investigator Administered and Scored (ADHDRS-IV-J:I) Total Score
NCT00191386 (4) [back to overview]	Change From Baseline at Various Timepoints in the Clinical Global Impressions-Attention Deficit Hyperactivity Disorder-Severity (CGI-ADHD-S)
NCT00191386 (4) [back to overview]	Cytochrome P450 2D6 (CYP2D6) Phenotype Status
NCT00191386 (4) [back to overview]	Number of Participants With Adverse Events for Long Term Safety and Tolerability
NCT00191906 (16) [back to overview]	Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset: Pseudo Words
NCT00191906 (16) [back to overview]	Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset: Pseudohomophones
NCT00191906 (16) [back to overview]	Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Hyperactivity-Impulsivity Subscale
NCT00191906 (16) [back to overview]	Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Inattention Subscale
NCT00191906 (16) [back to overview]	Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Total T-Score
NCT00191906 (16) [back to overview]	Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale
NCT00191906 (16) [back to overview]	Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale
NCT00191906 (16) [back to overview]	Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Total Score
NCT00191906 (16) [back to overview]	Change From Baseline in Mean Stop Signal Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset
NCT00191906 (16) [back to overview]	Change From Baseline in Mean Stop Signal Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset
NCT00191906 (16) [back to overview]	Lexical Decision Task Mean Reaction Time: Pseudo Words
NCT00191906 (16) [back to overview]	Lexical Decision Task Mean Reaction Time: Correct Words
NCT00191906 (16) [back to overview]	Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset: Pseudo Words
NCT00191906 (16) [back to overview]	Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset: Pseudohomophones
NCT00191906 (16) [back to overview]	Working Memory by Corsi Block Tapping Test (CBTT)
NCT00191906 (16) [back to overview]	Stop Signal Reaction Time (SSRT) as Derived From the Stop Signal Reaction Time Paradigm
NCT00191945 (15) [back to overview]	Vital Signs - Weight
NCT00191945 (15) [back to overview]	Vital Signs - Systolic Blood Pressure
NCT00191945 (15) [back to overview]	Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) at 107 Weeks (Open-Label Extension)
NCT00191945 (15) [back to overview]	Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score at 12 Week Endpoint
NCT00191945 (15) [back to overview]	Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score at 4 Weeks
NCT00191945 (15) [back to overview]	Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score at 6 Weeks
NCT00191945 (15) [back to overview]	Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score at 9 Weeks
NCT00191945 (15) [back to overview]	Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score Change From Week 6 to Week 12
NCT00191945 (15) [back to overview]	Child Health and Illness Profile (CHIP) Change From Baseline to Endpoint (12 Weeks)
NCT00191945 (15) [back to overview]	Clinical Global Impressions- Attention-Deficit/Hyperactivity Disorder-Severity Change From Baseline to Endpoint (Visit 18) of the Open-Label Extension (107 Weeks)
NCT00191945 (15) [back to overview]	Clinical Global Impressions- Attention-Deficit/Hyperactivity Disorder-Severity Changes From Baseline to Visit 7 (12 Weeks)
NCT00191945 (15) [back to overview]	Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S) Total Score Changes From Baseline to Endpoint (Week 12)
NCT00191945 (15) [back to overview]	Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version (K-SADS-PL)
NCT00191945 (15) [back to overview]	Vital Signs - Diastolic Blood Pressure
NCT00191945 (15) [back to overview]	Vital Signs - Pulse
NCT00192023 (10) [back to overview]	Open-Label Phase Nonserious Adverse Events
NCT00192023 (10) [back to overview]	Change From Baseline to 8 Week Endpoint in Screen for Child Anxiety Related Emotional Disorders (SCARED) Total Score
NCT00192023 (10) [back to overview]	Change From Baseline to 8 Week Endpoint in SNAP-IV Oppositional Subscale
NCT00192023 (10) [back to overview]	Change From Baseline to 8 Week Endpoint in Swanson, Nolan and Pelham Questionnaire (SNAP-IV): Attention-Deficit/Hyperactivity Disorder (ADHD) Subscale
NCT00192023 (10) [back to overview]	Change From Baseline to 8 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE): Parent Rated Form
NCT00192023 (10) [back to overview]	Change From Baseline to 8 Week Endpoint in Children's Depression Rating Scale-Revised
NCT00192023 (10) [back to overview]	Open-Label Phase Serious Adverse Events
NCT00192023 (10) [back to overview]	Change From Baseline to 8 Week Endpoint in Conners' Parent Rating Scale-Revised: Short Form Subscale Scores
NCT00192023 (10) [back to overview]	Change From Baseline to 8 Week Endpoint in Conners' Teacher Rating Scale-Revised: Short Form Subscale Scores
NCT00192023 (10) [back to overview]	Change From Baseline to 8 Week Endpoint in Clinical Global Impressions - Attention-Deficit/Hyperactivity Disorder (ADHD) - Severity
NCT00218543 (2) [back to overview]	ADHD Symptoms Based on Adult ADHD Rating Scale Scale (AARS)
NCT00218543 (2) [back to overview]	the Adult ADHD Rating Scale (AARS) (30% Reduction)
NCT00254462 (2) [back to overview]	Change in ADHD-IV Rating Scale Total Score
NCT00254462 (2) [back to overview]	Change in Total ADHD-IV Teacher
NCT00260533 (1) [back to overview]	Clinical Global Impression (Change Version, Also Known as Improvement Version)
NCT00286949 (3) [back to overview]	Clinical Global Impression of Change-Clinician Rated Score (CGIC-C)
NCT00286949 (3) [back to overview]	Frontal Systems Behavioral Scale (FrSBe) Executive Function Subscore
NCT00286949 (3) [back to overview]	Connors Adult Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale-Long Form (CAARS-L) Inattention/Memory Subscale
NCT00304161 (2) [back to overview]	Clinical Global Impression-Improvement Scale
NCT00304161 (2) [back to overview]	Inventory of Depressive Symptomatology- Clinician Rated (IDS-C) Scale
NCT00320528 (10) [back to overview]	Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain
NCT00320528 (10) [back to overview]	Change From Baseline to 12 Week Endpoint in the Attention-Deficit/Hyperactivity Disorder (ADHD) Subscales of 18-Item Swanson, Nolan and Pelham Rating Scale (SNAP-IV)
NCT00320528 (10) [back to overview]	Change From Baseline to 12 Week Endpoint in Children's Depression Rating Scale-Revised (CDRS-R)
NCT00320528 (10) [back to overview]	Change From Baseline to 12 Week Endpoint in Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S)
NCT00320528 (10) [back to overview]	Change From Baseline to 12 Week Endpoint in Pediatric Anxiety Rating Scale (PARS)
NCT00320528 (10) [back to overview]	Change From Baseline to 12 Week Endpoint in SNAP-IV Oppositional Scale
NCT00320528 (10) [back to overview]	Change From Baseline to 12 Week Endpoint in Adolescent Symptom Inventory-4: Parent Checklist (ASI-4)
NCT00320528 (10) [back to overview]	Change From Baseline to 12 Week Endpoint in Child Symptom Inventory-4: Parent Checklist (CSI-4)
NCT00320528 (10) [back to overview]	Change From Baseline to 12 Week Endpoint in CHIP-CE Satisfaction, Comfort, Resilience and Risk Avoidance Domains
NCT00320528 (10) [back to overview]	Change From Baseline to 12 Week Endpoint in Conners' Teacher Rating Scale-Revised: Short Form (CTRS-R:S)
NCT00360269 (5) [back to overview]	Urine Drug Screens
NCT00360269 (5) [back to overview]	Clinical Global Impression, Improvement Scale
NCT00360269 (5) [back to overview]	Estimated Week 12 Self-reported Use
NCT00360269 (5) [back to overview]	Self-reported Longitudinal Use
NCT00360269 (5) [back to overview]	Wender-Reimherr Adult Attention Deficit Disorder Scale
NCT00368849 (5) [back to overview]	Attention Composite Score
NCT00368849 (5) [back to overview]	Unified Huntington Disease Rating Scale (UHDRS) Total Motor Score
NCT00368849 (5) [back to overview]	Symptom Checklist-90-Revised (SCL-90-R)
NCT00368849 (5) [back to overview]	Executive Composite Score
NCT00368849 (5) [back to overview]	Conners' Adult Attention Rating Scale (CAARS)
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement
NCT00380692 (21) [back to overview]	Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)
NCT00380692 (21) [back to overview]	Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)
NCT00380692 (21) [back to overview]	Cytochrome P450 2D6 Genotype
NCT00380692 (21) [back to overview]	General Health Questionnaire (GHQ) Total Score
NCT00380692 (21) [back to overview]	Nijmeegse Ouderlijke Stress Index (NOSI) Total Score
NCT00380692 (21) [back to overview]	Sleep Measure Scale
NCT00380692 (21) [back to overview]	ADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score
NCT00380692 (21) [back to overview]	Children's Social Behavior Questionnaire (CSBQ) Total Score
NCT00380692 (21) [back to overview]	Aberrant Behavior Checklist (ABC)
NCT00380692 (21) [back to overview]	ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates
NCT00380692 (21) [back to overview]	Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates
NCT00399763 (3) [back to overview]	Time Line Followback Interview (TLFB)
NCT00399763 (3) [back to overview]	Side Effect Form for Children and Adolescents (SEFCA)
NCT00399763 (3) [back to overview]	Change in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Attention-deficit/Hyperactivity Disorder (ADHD) Checklist
NCT00406354 (22) [back to overview]	Investigator-Rated Individual Target Behaviors (ITB-Inv): Frequency Score
NCT00406354 (22) [back to overview]	Impact on Family Scale (FaBel), Total Impact Score
NCT00406354 (22) [back to overview]	Number of Patients Who Experienced Clinically Relevant Categories of Adverse Events During Initial Three Weeks of Study Treatment
NCT00406354 (22) [back to overview]	Clinical Global Impressions - Severity (CGI-S): ADHD Score
NCT00406354 (22) [back to overview]	German Revised Children's Quality of Life Questionnaire (KINDL-R): Self Esteem Score
NCT00406354 (22) [back to overview]	German Revised Children's Quality of Life Questionnaire (KINDL-R): Total Quality of Life Score
NCT00406354 (22) [back to overview]	German Revised Children's Quality of Life Questionnaire (KINDL-R): School Score
NCT00406354 (22) [back to overview]	Investigator-Rated Individual Target Behaviors (ITB-Inv): Intensity Score
NCT00406354 (22) [back to overview]	Parent-Rated Attention-Deficit Scale (FBB-HKS), Total Score: Severity
NCT00406354 (22) [back to overview]	Parent-Rated Oppositional Defiant/Conduct Disorders Scale (FBB-SSV): Total Score, Severity
NCT00406354 (22) [back to overview]	Swanson, Nolan & Pelham Rating Scale - Revised (SNAP-IV): ADHD Combined Score
NCT00406354 (22) [back to overview]	Swanson, Nolan & Pelham Rating Scale - Revised (SNAP-IV): ADHD Inattention Score
NCT00406354 (22) [back to overview]	Swanson, Nolan & Pelham Rating Scale - Revised (SNAP-IV): Hyperactivity/Impulsivity Score
NCT00406354 (22) [back to overview]	Swanson, Nolan and Pelham Rating Scale Revised (SNAP-IV) Oppositional Defiant Disorder: (ODD) Score
NCT00406354 (22) [back to overview]	Number of Participants Discontinuing Treatment
NCT00406354 (22) [back to overview]	Number of Patients Who Experienced Clinically Relevant Categories of Adverse Events During Nine-Week Study Treatment Period
NCT00406354 (22) [back to overview]	Clinical Global Impressions - Severity (CGI-S): Combined ADHD and ODD Scores
NCT00406354 (22) [back to overview]	Clinical Global Impressions - Severity (CGI-S): ODD Score
NCT00406354 (22) [back to overview]	German Revised Children's Quality of Life Questionnaire (KINDL-R): Emotional Well-Being Score
NCT00406354 (22) [back to overview]	German Revised Children's Quality of Life Questionnaire (KINDL-R): Family Score
NCT00406354 (22) [back to overview]	German Revised Children's Quality of Life Questionnaire (KINDL-R): Friends Score
NCT00406354 (22) [back to overview]	German Revised Children's Quality of Life Questionnaire (KINDL-R): Physical Well-Being Score
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Motor Tics
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Movements, Picking/Chewing Skin or Fingers
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Tearful/Sad/Depressed
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Socially Withdrawn
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Stomachaches
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Trouble Sleeping
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Worried/Anxious
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Crabby/Irritable
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Dull/Tired/Listless
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Hallucinations
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Headaches
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale: Loss of Appetite
NCT00418262 (15) [back to overview]	Compare Growth While on Atomoxetine With Growth Before Entry Into Study.
NCT00418262 (15) [back to overview]	Determine if Changes in Behavior Seen With Short-term (Eight Weeks) Treatment of Children Are Maintained Over a Twelve Month Period.
NCT00418262 (15) [back to overview]	Pittsburg Side-Effects Scale-Buccal, Lingual Movements
NCT00447278 (9) [back to overview]	Change From Baseline to 4 Month and 12 Month Endpoints in CHIP-CE PRF, Achievement Domain
NCT00447278 (9) [back to overview]	Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in Attention-Deficit/Hyperactivity Disorder Rating Scale - Parent Version: Investigator Adminitered and Scored (ADHD-RS-IV Parent:Inv)
NCT00447278 (9) [back to overview]	Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in Clinical Global Impression Attention-Deficit/Hyperactivity Disorder - Severity (CGI-ADHD-S)
NCT00447278 (9) [back to overview]	Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in the CHIP-Adolescent Edition (AE) for Adolescents (>11-17 Years)
NCT00447278 (9) [back to overview]	Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in the CHIP-CE PRF Domain Scores (Satisfaction, Comfort, Resilience and Risk Avoidance)
NCT00447278 (9) [back to overview]	Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P)
NCT00447278 (9) [back to overview]	Change From Baseline to 6 Month Endpoint in Child Health and Illness Profile - Child Edition, Parent Report Form (CHIP-CE PRF), Achievement Domain
NCT00447278 (9) [back to overview]	Correlation Between CHIP-CE Parent Rated and Pooled CHIP-CE Child Rated and CHIP AE Adolescent Rated T-Scores
NCT00447278 (9) [back to overview]	Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in the CHIP-CE CRF for Children (6-11 Years)
NCT00471354 (7) [back to overview]	Correlation Between Change From Baseline to 24 Week Endpoint in ADHDRS-IV-Parent:Inv Total Score and School Grade Averages in Separate Language, Math and Science Classes
NCT00471354 (7) [back to overview]	Change From Baseline to 24 Week Endpoint in Academic Performance by School Grade Average (SGA) Total, and Separate Language, Math, and Science Scores
NCT00471354 (7) [back to overview]	CGI-ADHD-Improvement Scale (CGI-ADHD-I) at 24 Week Endpoint
NCT00471354 (7) [back to overview]	Change From Baseline to 24 Week Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored - Total Score
NCT00471354 (7) [back to overview]	Change From Baseline to 24 Week Endpoint in Clinical Global Impressions - Attention-Deficit/Hyperactivity Disorder - Severity Scale (CGI-ADHD-S)
NCT00471354 (7) [back to overview]	Change From Baseline to 24 Week Endpoint in Revised Conners' Parent Rating Scale: Short Form (CPRS-R:S) Attention-Deficit/Hyperactivity Disorder Index Score
NCT00471354 (7) [back to overview]	Correlation Between Change From Baseline and 24 Week Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent:Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score and School Grade Average (SGA)
NCT00498173 (15) [back to overview]	Change in Social Responsiveness Scale (SRS) (Open-label Trial)
NCT00498173 (15) [back to overview]	Change in ADHD Rating Scale (ADHDRS)-Home Version Total Score (Open-label Trial)
NCT00498173 (15) [back to overview]	ADHD Rating Scale (ADHDRS)-Home Version Total Score (Randomized Phase)
NCT00498173 (15) [back to overview]	Change in Aberrant Behavior Checklist (ABC) (Open-label Trial)
NCT00498173 (15) [back to overview]	ADHD Rating Scale (ADHDRS)-Home Version Inattention and Hyperactivity Scores (Randomized Phase)
NCT00498173 (15) [back to overview]	Aberrant Behavior Checklist (ABC) (Randomized Phase)
NCT00498173 (15) [back to overview]	Vineland Adaptive Behavior Scales (VABS) Composite Score (Randomized Phase)
NCT00498173 (15) [back to overview]	Social Responsiveness Scale (SRS) (Randomized Phase)
NCT00498173 (15) [back to overview]	Change in ADHD Rating Scale (ADHDRS)-Home Version Inattention and Hyperactivity Scores (Open-label Trial)
NCT00498173 (15) [back to overview]	Pediatric Anxiety Rating Scale, 5-Item Total (Randomized Phase)
NCT00498173 (15) [back to overview]	Odds of Clinical Global Impression-Improvement Scale, Very Much or Much Improved (1 or 2) (Randomized Phase)
NCT00498173 (15) [back to overview]	Change in Vineland Adaptive Behavior Scales (VABS) Composite Score (Open-label Trial)
NCT00498173 (15) [back to overview]	Change in Pediatric Anxiety Rating Scale, 5-item Total (Open-label Trial)
NCT00498173 (15) [back to overview]	Change in Pediatric Quality of Life Inventory (Open-label Trial)
NCT00498173 (15) [back to overview]	Pediatric Quality of Life Inventory (Randomized Phase)
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Epworth Sleepiness Scale (ESS)
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Drugs
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Nicotine
NCT00510276 (39) [back to overview]	Mean Change in the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptom Score From Baseline to 12 Week Endpoint
NCT00510276 (39) [back to overview]	Responders by Baseline Smoking Status
NCT00510276 (39) [back to overview]	Strong Responders by Baseline Smoking Status
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12 Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Alcohol
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12 Week Endpoint on the Fagerstrom Test for Nicotine Dependence (FTND)
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12 Week Endpoint on the Beck Anxiety Inventory (BAI)
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12 Week Endpoint in Clinical Global Impression-ADHD- Severity (CGI-ADHD-S)
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12 Week Endpoint in CAARS Self Report (CAARS-S:SV) Total Score
NCT00510276 (39) [back to overview]	Endpoint Scores in Patient Global Impression - Improvement (PGI-I)
NCT00510276 (39) [back to overview]	Correlation of Mean Changes From Baseline to 12 Week on the Adult ADHD Quality of Life-29 Total Score and of Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated:Screening Version Total Score
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12 Week Endpoint on the Montgomery Asberg Depression Rating Scale (MADRS)
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Caffeine
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12 Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Marijuana
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Life Outlook Subscale
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Life Productivity Subscale
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Psychological Health Subscale
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Relationship Subscale
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Organization of Materials Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Plan/Organize Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Self Monitor Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Total Score
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Behavioral Regulation Section Score
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Emotional Control Section Score
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - GEC Section Score
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Inconsistency Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Infrequency Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12 Week Endpoint on the Social Adaptation Self-Evaluation Scale (SASS)
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Initiate Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Metacognition Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Negativity Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - SHIFT Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Task Monitor Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Working Memory Section
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Driving Behavior Survey Self-Report
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Driving Behavior Survey-Other Report
NCT00510276 (39) [back to overview]	Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Inhibit Section
NCT00530335 (12) [back to overview]	Cytochrome P450 2D6 (CYP2D6) Phenotype Status
NCT00530335 (12) [back to overview]	Number of Participants With Abnormal QTc Interval Based on International Conference on Harmonisation Criterion
NCT00530335 (12) [back to overview]	Number of Participants With Adverse Events Leading to Discontinuation
NCT00530335 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Changes in Body Weight During the Study
NCT00530335 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Changes in Vital Signs During the Study
NCT00530335 (12) [back to overview]	Change From Endpoint to Baseline in Clinical Global Impression-ADHD - Severity
NCT00530335 (12) [back to overview]	Change From Endpoint to Baseline in Hamilton Anxiety Rating Scale - 14 Items (HAMA) Total Score
NCT00530335 (12) [back to overview]	Change From Endpoint to Baseline in 36-item Short-Form Health Survey (SF-36v2) Norm-based Subdomain and Summary Scores
NCT00530335 (12) [back to overview]	Change From Endpoint to Baseline in Hamilton Depression Rating Scale - 17 Items (HAMD-17) Total Score
NCT00530335 (12) [back to overview]	Change From Endpoint to Baseline in Connors's Adult ADHD Rating Scale-Investigator Rated: Screening Version - Japanese Version (CAARS-Inv:SV-J)
NCT00530335 (12) [back to overview]	Change From Endpoint to Baseline in Connors's Adult ADHD Rating Scale-Self Report: Screening Version - Japanese Version (CAARS-S:SV-J)
NCT00530335 (12) [back to overview]	Change From Endpoint to Baseline in Stroop Color Word Test
NCT00546910 (7) [back to overview]	Change From Baseline cb CPT Variable: Impulsivity (Includes Commission Error [CE], Anticipatory Response [AR]) Q-scores At Week 8
NCT00546910 (7) [back to overview]	Change From Baseline Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered And Scored (ADHDRS-IV-Parent:Inv) Total Score At Week 8
NCT00546910 (7) [back to overview]	Change From Baseline cb CPT Variable: Inattention (Includes Reaction Time Variation[RTV], Omission Error [OR], Mean Reaction Time [mRT], Normalized Variation Of Reaction Time [nVRT]) Q-scores At Week 8
NCT00546910 (7) [back to overview]	Change From Baseline cb CPT Variable: Other (Includes Error Rate [ER] and Multi Response [MR]) Q-scores At Week 8
NCT00546910 (7) [back to overview]	Change From Baseline Clinical Global Impressions-Severity of ADHD (CGI-S-ADHD) Score at Week 8
NCT00546910 (7) [back to overview]	Change From Baseline Computer-based Continuous Performance Test (cb- CPT; Qbtech AB, Sweden), Variable: Hyperactivity (Includes Time Active [TA], Distance [DIS], Area [AR], Microevents [ME], Motion Simplicity [MS]) Q-scores At Week 8
NCT00546910 (7) [back to overview]	Change From Baseline Weekly Rating Of Evening and Morning Behavior-Revised-Investigator Rated, Total and Subscores at Week 8
NCT00568685 (9) [back to overview]	Change From Baseline to Day 42 Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score
NCT00568685 (9) [back to overview]	Incidence of Completion of the Columbia Suicide-Severity Rating Scale, Suicide and Self-Harm Summary
NCT00568685 (9) [back to overview]	Adverse Events Leading to Discontinuation
NCT00568685 (9) [back to overview]	Blood Pressure Change From Baseline to Day 42 Endpoint
NCT00568685 (9) [back to overview]	Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint
NCT00568685 (9) [back to overview]	Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint
NCT00568685 (9) [back to overview]	Heart Rate Change From Baseline to Day 42 Endpoint
NCT00568685 (9) [back to overview]	Temperature Change From Baseline to Day 42 Endpoint
NCT00568685 (9) [back to overview]	Weight Change From Baseline to Day 42 Endpoint
NCT00573859 (3) [back to overview]	The Interacting Effects of Smoking and Overnight Abstinence With ADHD Medication and Placebo on Continuous Performance Task (CPT) Errors of Omission.
NCT00573859 (3) [back to overview]	The Interacting Effects of Smoking and Abstinence With ADHD Medication and Placebo on Nicotine Withdrawal Measured by the Shiffman-Jarvik Withdrawal Questionnaire.
NCT00573859 (3) [back to overview]	The Effects of ADHD Medication Versus Placebo on Cotinine Levels
NCT00585910 (2) [back to overview]	Clinical Global Impressions - Level of Severity (CGIs) for ADHD and Other Psychiatric Disorders
NCT00585910 (2) [back to overview]	Attention Deficit Hyperactivity Disorder Rating Scale (ADHD RS)
NCT00607919 (21) [back to overview]	Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total Score - Parent Version at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 Endpoint
NCT00607919 (21) [back to overview]	Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 Endpoint
NCT00611533 (5) [back to overview]	Weight
NCT00611533 (5) [back to overview]	BADDS Total Score
NCT00611533 (5) [back to overview]	Heart Rate
NCT00611533 (5) [back to overview]	Blood Pressure
NCT00611533 (5) [back to overview]	Brown Attention Deficit Disorder Scale
NCT00617201 (2) [back to overview]	Retention
NCT00617201 (2) [back to overview]	% Urine Samples Negative for Cocaine
NCT00628394 (2) [back to overview]	Neuropsychological Measures for MATRICS
NCT00628394 (2) [back to overview]	Clinical Outcomes
NCT00636818 (12) [back to overview]	Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-ADHD Severity (CGI-ADHD-S)
NCT00636818 (12) [back to overview]	Change From Baseline to 8 Week Endpoint in Conners' Adult ADHD Rating Scale-Self Rated:Screening Version (CAARS-S:SV) Total ADHD Symptom Score
NCT00636818 (12) [back to overview]	Significant Changes in Body Weight During the Study
NCT00636818 (12) [back to overview]	Change From Baseline to 8 Week Endpoint in Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale-Investigator Rated:Screening Version (CAARS-Inv:SV) Total ADHD Symptom Score
NCT00636818 (12) [back to overview]	Change From Baseline to 8 Week Endpoint in Stroop Color Word Test
NCT00636818 (12) [back to overview]	Cytochrome P450 2D6 (CYP2D6) Phenotype Status
NCT00636818 (12) [back to overview]	Discontinuations Due to Adverse Events (AE)
NCT00636818 (12) [back to overview]	Number of Participants With Abnormal QTc Interval Based on International Conference on Harmonisation Criterion
NCT00636818 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Changes in Vital Signs During the Study
NCT00636818 (12) [back to overview]	Change From Baseline to 8 Week Endpoint in Short Form-36 Version 2 (SF-36v2)
NCT00636818 (12) [back to overview]	Change From Baseline to 8 Week Endpoint in Hamilton Anxiety Rating Scale (HAMA-14)
NCT00636818 (12) [back to overview]	Change From Baseline to 8 Week Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17)
NCT00687609 (2) [back to overview]	C-SSRS Intensity of Ideation (Most Common Ideation Type and Most Severe Ideation Type) By Visit at Week 4
NCT00687609 (2) [back to overview]	C-SSRS Suicidal Ideation By Visit at Week 4: Non-Specific Active Suicidal Thoughts
NCT00700427 (8) [back to overview]	Change From Baseline in the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life (AAQoL) Scale From Week 24 to Week 49
NCT00700427 (8) [back to overview]	Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version: Self Report (BRIEF-A:Self Report) Global Executive Composite (GEC) Index Score From Week 24 to Week 49
NCT00700427 (8) [back to overview]	Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version:Informant Report (BRIEF-A:Informant) Global Executive Composite (GEC) Index Score From Week 24 to Week 49
NCT00700427 (8) [back to overview]	Number of Days Until Relapse
NCT00700427 (8) [back to overview]	Percentage of Participants Who Maintain a Satisfactory Response During the Double-Blind Maintenance/Randomized Withdrawal Period
NCT00700427 (8) [back to overview]	Change From Baseline in Conner's Adult ADHD Rating Scale-Self Rated (CARRS-S:SV) Total ADHD Symptom Score From Week 24 to Week 49
NCT00700427 (8) [back to overview]	Change From Baseline in Conner's Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (Observer Rated [CAARS-O:SV]) Total ADHD Symptom Score From Week 24 to Week 49
NCT00700427 (8) [back to overview]	Change From Baseline in European Quality of Life (EuroQoL) Questionnaire-5 Dimensions (EQ-5D) Index Score From Week 24 to Week 49
NCT00702364 (4) [back to overview]	Adult Attention Deficit Hyperactivity Disorder (ADHD) Self-Report Scale Summary Score
NCT00702364 (4) [back to overview]	CDR Power of Attention
NCT00702364 (4) [back to overview]	Neurobehavioral Functioning Inventory Depression Subscale
NCT00702364 (4) [back to overview]	Stroop Test Interference T-score
NCT00716274 (77) [back to overview]	The Number of Participants With TEAE in Participants With Dyslexia
NCT00716274 (77) [back to overview]	The Number of Participants With Treatment Emergent Adverse Events (TEAE) in Participants With Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in ADHDRS-IV-Parent: Inv Total Score in Participants With ADHD or ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in ADHDRS-IV-Parent: Inv Total Score in Participants With ADHD or ADHD +Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version (ADHDRS) Total Score in the ADHD or ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in BADD-A Total Score in Participants With ADHD or ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in BADD-A Total Score in Participants With ADHD or ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Comprehensive Test of Phonological Processing (CTOPP) Composite Scores in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in CTOPP Composite Score in Participants With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in CTOPP Composite Score in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in CTOPP Composite Scores in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in CTOPP Composite Scores in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in CTOPP Composite Scores in Participants With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in CTOPP Composite Scores in Participants With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in CTOPP Composite Scores in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in CTOPP Composite Scores in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in CTOPP Composite Scores in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in CTOPP Composite Scores in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in fMRI Activation in Participants With ADHD or ADHD + Dyslexia (Pseudoword Rhyming and Semantic-category Tasks)
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Functional Magnetic Resonance Imaging (fMRI) Activation in Participants With Dyslexia Alone (Pseudoword Rhyming and Semantic-category)
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in GORT-4 in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in GORT-4 in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in GORT-4 in Participants With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in GORT-4 in Participants With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in GORT-4 in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in GORT-4 in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in GORT-4 in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in GORT-4 in Participants With ADHD+ Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in BADD-A Total Score in Participants With ADHD or ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in GORT-4 in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Gray Oral Reading Tests-4 (GORT-4) in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Participants in TOWRE Total Score With ADHD or ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Participants in WMTB-C With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Participants in WMTB-C With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Participants in WMTB-C With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in TOWRE Total Score in Participants With ADHD or ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in TOWRE Total Score in Participants With ADHD or ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Scores in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Scores in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Scores in Participants With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Scores in Participants With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Scores in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Scores in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Scores in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Scores in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Test Scores in Participants With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Test Scores in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WJ III Individual Test Scores in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WMTB-C in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WMTB-C in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in WMTB-C in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Working Memory Test Battery for Children (WMTB-C) in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint WMTB-C in Participants With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint WMTB-C in Participants With ADHD + Dyslexia
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint WMTB-C in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint WMTB-C in Participants With ADHD Alone
NCT00716274 (77) [back to overview]	The Number of Participants With TEAE in Participants With ADHD or ADHD+Dyslexia.
NCT00716274 (77) [back to overview]	The Number of Participants With TEAE in Participants With ADHD or ADHD+Dyslexia.
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in GORT-4 in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in ADHDRS-IV Total Score in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in ADHDRS-IV Total Score in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in ADHDRS-IV Total Score in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in ADHDRS-IV-Parent: Inv Total Score in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in ADHDRS-IV-Parent: Inv Total Score in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in BADD-A Total Score in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in BADD-A Total Score in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in BADD-A Total Score in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in BADD-A Total Score in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in BADD-A Total Score in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Basic Reading Skills Cluster WJ III in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Participants in TOWRE Total Score With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in TOWRE Total Score in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint in Woodcock Johnson Tests of Achievement (WJ III) Word Attack Total Score in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint Test of Word Reading Efficiency (TOWRE) Total Score in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint TOWRE Total Score in Healthy Participants
NCT00716274 (77) [back to overview]	Change From Baseline to Endpoint TOWRE Total Score in Participants With Dyslexia Alone
NCT00716274 (77) [back to overview]	Number of Participants With Adverse Events
NCT00760747 (12) [back to overview]	Change From Baseline in Clinical Global Impression Severity (CGI-S) Rating Scale - Total Score at Week 10 Endpoint
NCT00760747 (12) [back to overview]	Change From Baseline in Child Health and Illness Profile Child Edition-Parent Report Form (CHIP-CE-PRF) - Domain Scores at Week 10 Endpoint
NCT00760747 (12) [back to overview]	Change From Baseline in ADHD-RS-IV Parent Version: Investigator Administered and Scored - Total Score at Week 2 Endpoint
NCT00760747 (12) [back to overview]	Change From Baseline in Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS-IV) Parent Version: Investigator Administered and Scored - Total Score at Week 10 Endpoint
NCT00760747 (12) [back to overview]	Change From Baseline in Global Impression of Perceived Difficulties (GIPD) Rating Scale - Patient Total Score at Week 10 Endpoint
NCT00760747 (12) [back to overview]	Change From Baseline in Global Impression of Perceived Difficulties (GIPD) Rating Scale- Investigator Total Score at Week 10 Endpoint
NCT00760747 (12) [back to overview]	Change From Baseline in Global Impression of Perceived Difficulties (GIPD) Rating Scale- Parent Total Score at Week 10 Endpoint
NCT00760747 (12) [back to overview]	Change From Baseline in Treatment Satisfaction Preference Survey Mean Score at Week 10 Endpoint
NCT00760747 (12) [back to overview]	Change From Baseline in Pulse Rate at Week 6 and Week 14 Endpoint
NCT00760747 (12) [back to overview]	Number of Participants With Suicidal Behaviors and Ideations
NCT00760747 (12) [back to overview]	Change From Baseline in Blood Pressure (BP) at Week 6 and Week 14 Endpoint
NCT00760747 (12) [back to overview]	Change From Baseline in Body Weight at Week 6 and Week 14 Endpoint
NCT00844753 (2) [back to overview]	Percentage of Participants Who Were Attention Deficit Hyperactivity Disorder (ADHD) Respondents
NCT00844753 (2) [back to overview]	Percentage of Participants Who Were Autism Spectrum Disorder Respondents
NCT00918567 (11) [back to overview]	Disruptive Behavior Disorder Rating Scale ODD Subscale(DBD- Teacher Completed) at Endpoint
NCT00918567 (11) [back to overview]	Disruptive Behavior Disorders Rating Scale ODD Subscale (DBD- Parent Completed) at Endpoint
NCT00918567 (11) [back to overview]	Impairment Rating Scale (Parent Completed) at Endpoint
NCT00918567 (11) [back to overview]	Impairment Rating Scale (Teachers) at Endpoint
NCT00918567 (11) [back to overview]	Pittsburgh Side Effects Rating Scale (PSERS)(Parent Completed) at Endpoint:
NCT00918567 (11) [back to overview]	Rule Violations During Direct Classroom Observation at Endpoint (Week 8)
NCT00918567 (11) [back to overview]	Social Skills Rating Scale Problem Behavior Subscale(SSRS Parent) at Endpoint
NCT00918567 (11) [back to overview]	Social Skills Rating Scale Problem Behavior Subscale(SSRS Teachers) at Endpoint
NCT00918567 (11) [back to overview]	Pittsburgh Side Effects Rating Scale (PSERS)(Teacher Rated):
NCT00918567 (11) [back to overview]	ADHD Subscale of the DBD (Parent Completed) at Endpoint
NCT00918567 (11) [back to overview]	ADHD Subscale of the DBD (Teacher Completed) at Endpoint
NCT00953862 (3) [back to overview]	Change in Clinical Global Impression-- Severity of Illness Score
NCT00953862 (3) [back to overview]	Change in Adult ADHD Symptom Rating Scale v1.1 Symptom Checklist Score
NCT00953862 (3) [back to overview]	Change in Adult ADHD Investigator Symptom Rating Scale Score
NCT00962104 (11) [back to overview]	The Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Self Report: Screening Version (CAARS-S:SV) 18 Item Total Attention-Deficit/Hyperactivity Disorder (ADHD) Symptom Score at 10 Weeks
NCT00962104 (11) [back to overview]	Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version: Informant (BRIEF-A: Informant) Score up to 10 Weeks
NCT00962104 (11) [back to overview]	Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version: Self Report (BRIEF-A:Self Report) Score up to 10 Weeks
NCT00962104 (11) [back to overview]	Change From Baseline in the Clinical Global Impression-Attention Deficit/Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) up to 10 Weeks
NCT00962104 (11) [back to overview]	Change From Baseline in the European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score up to 10 Weeks
NCT00962104 (11) [back to overview]	Change From Baseline in the Hamilton Anxiety Rating Scale-14 Items (HAMA-14) up to 10 Weeks
NCT00962104 (11) [back to overview]	Change From Baseline in the Hamilton Depression Rating Scale-17 Items (HAMD-17 Total) up to 10 Weeks
NCT00962104 (11) [back to overview]	Change From Baseline in the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life-29 (AAQoL) Scores up to 10 Weeks
NCT00962104 (11) [back to overview]	Change From Baseline in the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) 18-Item Total Attention-Deficit/Hyperactivity Disorder (ADHD) Symptom Score up to 10 Weeks
NCT00962104 (11) [back to overview]	Clinical Global Impression-Attention Deficit/Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) up to 10 Weeks
NCT00962104 (11) [back to overview]	The Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) 18-Item Total Attention-Deficit/Hyperactivity Disorder (ADHD) Symptom Score at 10 Weeks
NCT00969618 (8) [back to overview]	Number of Participants With Adverse Events Leading to Discontinuation
NCT00969618 (8) [back to overview]	Mean Change From Baseline to 48 Weeks Endpoint in the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life (AAQoL)-29 Scores
NCT00969618 (8) [back to overview]	Mean Change From Baseline to 48 Weeks Endpoint in Comorbid, Depressive Symptoms, as Measured by Hamilton Depression Rating Scale-17 (HAMD-17) Items
NCT00969618 (8) [back to overview]	Mean Change From Baseline to 48 Weeks Endpoint in Comorbid, Anxiety Symptoms, as Measured by Hamilton Anxiety Rating Scale-14 (HAMA-14) Items
NCT00969618 (8) [back to overview]	Mean Change From Baseline to 48 Weeks Endpoint in the Conners' Adult Attention-Deficit Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version-Japanese (CAARS-Inv:SV-J)
NCT00969618 (8) [back to overview]	Mean Change From Baseline to 48 Weeks Endpoint in the Behavior Rating Inventory of Executive Function-Adult (BRIEF-A) Version: Informant Scores (BRIEF-A:Informant Scores)
NCT00969618 (8) [back to overview]	Mean Change From Baseline to 48 Weeks Endpoint in the Behavior Rating Inventory of Executive Function -Adult (BRIEF-A) Version: Self Report (BRIEF-A:Self Report )
NCT00969618 (8) [back to overview]	Mean Change From Baseline to 48 Weeks Endpoint in Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity (CGI-ADHD-S)
NCT01019707 (3) [back to overview]	Heart Rate
NCT01019707 (3) [back to overview]	Systolic Blood Pressure
NCT01019707 (3) [back to overview]	Diastolic Blood Pressure
NCT01106430 (8) [back to overview]	Health Utilities Index-2 (HUI-2) Scores at Up to 9 Weeks
NCT01106430 (8) [back to overview]	Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Up to 9 Weeks
NCT01106430 (8) [back to overview]	Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at 9 Weeks - LOCF
NCT01106430 (8) [back to overview]	Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Up to 9 Weeks
NCT01106430 (8) [back to overview]	Udvalg for Kliniske Undersogelser Side Effect Rating Scale - Clinician (UKU-SERS-Clin) With Side Effects Scores >=1
NCT01106430 (8) [back to overview]	Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01106430 (8) [back to overview]	Time to First Response
NCT01106430 (8) [back to overview]	Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores - Last Observation Carried Forward (LOCF)
NCT01127646 (2) [back to overview]	Change From Baseline in Heart Rate up to 5 Weeks
NCT01127646 (2) [back to overview]	Change From Baseline in Systolic and Diastolic Blood Pressure up to 5 Weeks
NCT01133847 (11) [back to overview]	Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Hyperactivity-impulsivity
NCT01133847 (11) [back to overview]	Test of Word Reading Efficiency (TOWRE) - Sight Word Efficiency
NCT01133847 (11) [back to overview]	Wechsler Individual Achievement Test-III (WIAT-III) Pseudoword Decoding Subtest
NCT01133847 (11) [back to overview]	Wechsler Individual Achievement Test-III (WIAT-III) Word Reading Subtest
NCT01133847 (11) [back to overview]	Test of Silent Reading Fluency and Comprehension (TOSREC)
NCT01133847 (11) [back to overview]	Wechsler Individual Achievement Test-III (WIAT-III) Reading Comprehension Subtest
NCT01133847 (11) [back to overview]	Dynamic Indicators of Basic Early Literacy Skills Oral Reading Fluency Subtest (DIBELS ORF)
NCT01133847 (11) [back to overview]	Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Hyperactivity-impulsivity
NCT01133847 (11) [back to overview]	Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Inattention
NCT01133847 (11) [back to overview]	Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Inattention
NCT01133847 (11) [back to overview]	Test of Word Reading Efficiency (TOWRE) - Phonemic Decoding Efficiency
NCT01177943 (2) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tlast)]
NCT01177943 (2) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT01244490 (16) [back to overview]	Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 10/13 - LOCF
NCT01244490 (16) [back to overview]	Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
NCT01244490 (16) [back to overview]	Clinical Global Impression-Severity of Illness (CGI-S) - LOCF
NCT01244490 (16) [back to overview]	Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01244490 (16) [back to overview]	Change From Baseline in the WFIRS-P Family Domain Score at Week 10/13 - LOCF
NCT01244490 (16) [back to overview]	Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF)
NCT01244490 (16) [back to overview]	Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Weeks 10/13 - LOCF
NCT01244490 (16) [back to overview]	Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 10/13 - LOCF
NCT01244490 (16) [back to overview]	Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 10/13 - LOCF
NCT01244490 (16) [back to overview]	Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 10/13 - LOCF
NCT01244490 (16) [back to overview]	Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 10/13 - LOCF
NCT01244490 (16) [back to overview]	Structure Side-Effect Questionnaire
NCT01244490 (16) [back to overview]	Change From Baseline in the WFIRS-P Risk Domain Score at Week 10/13 - LOCF
NCT01244490 (16) [back to overview]	Change From Baseline in the WFIRS-P Social Domain Score at Week 10/13 - LOCF
NCT01244490 (16) [back to overview]	Health Utilities Index-2/3 (HUI 2/3) Scores - LOCF
NCT01244490 (16) [back to overview]	Change From Baseline in the WFIRS-P Global Score at Week 10/13 - LOCF
NCT01399827 (5) [back to overview]	Efficacy Measured by Mean Change From Baseline to Endpoint on BRIEF-A Subscales
NCT01399827 (5) [back to overview]	Efficacy Measured by Mean Change From Baseline to Endpoint on Adult ADHD Investigator Rating Scale (AISRS) Total Score
NCT01399827 (5) [back to overview]	Efficacy Measured by Mean Change From Baseline to Endpoint on Clinical Global Impression (CGI) Scale
NCT01399827 (5) [back to overview]	Efficacy Measured by Mean Change From Baseline to Endpoint on the Global Assessment of Functioning (GAF) Scale
NCT01399827 (5) [back to overview]	Mean Change From Baseline to Endpoint on the BRIEF-A Emotional Control Scale
NCT01498549 (2) [back to overview]	Rapid Visual Information Processing: Mean Correct Response Latency
NCT01498549 (2) [back to overview]	Rapid Visual Information Processing
NCT01522404 (5) [back to overview]	Change in Mean Level of Thymus-Expressed Chemokine (TECK) in Cerebrospinal Fluid (CSF) in Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine
NCT01522404 (5) [back to overview]	Change in FluoroDeoxyGlucose (FDG) Uptake in Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine
NCT01522404 (5) [back to overview]	Number of Participants That Drop Out of the Study Among the Participants Treated With Atomoxetine When Compared to the Participants Treated With Inactive Compound (Placebo)
NCT01522404 (5) [back to overview]	Number of All Adverse Events Among the Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine Compared to the Participants Treated With Placebo/Inactive Compound
NCT01522404 (5) [back to overview]	Rate of Cerebral Blood Flow in Subjects With Mild Cognitive Impairment MCI Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine
NCT01557569 (1) [back to overview]	Time Till Relapse
NCT01678209 (7) [back to overview]	Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale (ADHD-RS)
NCT01678209 (7) [back to overview]	Clinical Global Impressions-Severity (CGI-S)
NCT01678209 (7) [back to overview]	Continuous Performance Test (CPT)
NCT01678209 (7) [back to overview]	Digit Span
NCT01678209 (7) [back to overview]	Finger Windows
NCT01678209 (7) [back to overview]	Percentage of Correct Inhibition in Participants Assessed With the Go-No go Task
NCT01678209 (7) [back to overview]	Response Time in Attention Networks Test (ANT)
NCT01738191 (8) [back to overview]	The Global Statistical Test Combined Information on Change From Baseline on a Battery of Standardized Executive Function Tests
NCT01738191 (8) [back to overview]	Change in D-KEFS: Inhibition Time
NCT01738191 (8) [back to overview]	Change in D-KEFS: Inhibition-Switching Time
NCT01738191 (8) [back to overview]	Change in D-KEFS: Number-Letter Switching Time
NCT01738191 (8) [back to overview]	Change in NAB: Part A
NCT01738191 (8) [back to overview]	Change in NAB: Part D
NCT01738191 (8) [back to overview]	Change in PASAT
NCT01738191 (8) [back to overview]	Change in WAIS-IV: Digit Span
NCT01802515 (2) [back to overview]	Change Score in the Center for Epidemiological Studies-Depression (CES-D) Scale
NCT01802515 (2) [back to overview]	Treatment Retention
NCT02287038 (2) [back to overview]	Conners' Adult ADHD Rating Scales-Self-Report: Short Version (CAARS-S:S, Conner et al, 1999)
NCT02287038 (2) [back to overview]	The Adult ADHD Quality of Life-29 (AAQOL-29, Brod et al, 2006)
NCT02500732 (5) [back to overview]	Cardiac Index (From the Continuous BP Monitor) During Presyncope
NCT02500732 (5) [back to overview]	Systematic Vascular Resistance Index (From the Continuous BP Monitor) During Presyncope
NCT02500732 (5) [back to overview]	Number of Participants Who Become Syncopal Associated With Diagnostic Criteria of Hypotension and Bradycardia
NCT02500732 (5) [back to overview]	Number of Participants Who Become Presyncopal (Isolated) Associated With Diagnostic Criteria of Hypotension and Bradycardia
NCT02500732 (5) [back to overview]	Estimated Stroke Volume Index (From the Continuous BP Monitor) During Presyncope
NCT02784535 (3) [back to overview]	Change in Heart Rate (HR)
NCT02784535 (3) [back to overview]	Change in Blood Pressure
NCT02784535 (3) [back to overview]	Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score
NCT02788357 (3) [back to overview]	Change in Fugl Meyer Assessment
NCT02788357 (3) [back to overview]	Change in Action Arm Research Test (ARAT)
NCT02788357 (3) [back to overview]	Change in Wolf Motor Function Test (WMFT)
NCT02908529 (2) [back to overview]	Genioglossus Muscle Responsiveness to Increased Ventilatory Drive (Esophageal Pressure Swings)
NCT02908529 (2) [back to overview]	Apnea Hypopnea Index (AHI, Events/Hour of Sleep)
NCT03091400 (6) [back to overview]	Change in Memory Change
NCT03091400 (6) [back to overview]	Change in CANTAB Paired Associate Learning
NCT03091400 (6) [back to overview]	Change in NIH Toolbox Picture Sequence Memory Test
NCT03091400 (6) [back to overview]	Change in Perceived Deficits Questionnaire (PDQ)
NCT03091400 (6) [back to overview]	Change in Patient-Reported Memory Change
NCT03091400 (6) [back to overview]	Change in Symbol Digit Modalities Test
NCT03154359 (11) [back to overview]	Plasma Concentration of 3,4-dihydroxyphenylglycol (DHPG)
NCT03154359 (11) [back to overview]	Plasma Concentration of 3,4-dihydroxyphenylglycol (DHPG)
NCT03154359 (11) [back to overview]	Maximum Plasma Concentration (Cmax) of Atomoxetine
NCT03154359 (11) [back to overview]	Maximum Plasma Concentration (Cmax) of Atomoxetine
NCT03154359 (11) [back to overview]	Maximum Plasma Concentration (Cmax) of Atomoxetine
NCT03154359 (11) [back to overview]	Change in Plasma Concentration of DHPG From Baseline
NCT03154359 (11) [back to overview]	Change in Plasma Concentration of DHPG From Baseline
NCT03154359 (11) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC) of Atomoxetine
NCT03154359 (11) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC) of Atomoxetine
NCT03154359 (11) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC) of Atomoxetine
NCT03154359 (11) [back to overview]	Plasma Concentration of 3,4-dihydroxyphenylglycol (DHPG)
NCT03324581 (1) [back to overview]	Change From Baseline in Conners' Adult ADHD Rating Scales-Observer: Screening Version (CAARS-O:SV) 18-item ADHD Symptoms Total Score at Day 56
NCT04445688 (3) [back to overview]	Apnea-Hypopnea Index
NCT04445688 (3) [back to overview]	Hypoxic Burden
NCT04445688 (3) [back to overview]	ODI
NCT04580394 (1) [back to overview]	Change in Hypoxic Burden (HB) Log10HB[(%*Min)/Hour]
NCT05101122 (1) [back to overview]	Apnea-Hypopnea Index (AHI)4% Events Per Hour

The Adult AISRS

The Adult AISRS was used to assess each of the 18 individual criteria symptoms (both inattentive and hyperactive) of ADHD in DSMIV on a severity grid (0=not present; 3=severe; minimum score=0; maximum score=54). Results are given as average change (reduction) in AISRS symptoms from baseline to Week 6. (NCT00181766)
Timeframe: baseline and 6 Weeks

Intervention	scores on a scale (Mean)
Strattera (Atomoxetine)	-12.1

Intervention	units on a scale (Mean)
	Block 1 Baseline Week 0	Block 1 End of Treatment Week 6	Block 2 Baseline Week 8	Blocks 2 End of Treatment Week 14
Atomoxetine Then Methylphenidate	.196	.053	.000	.160
Methylphenidate Then Atomoxetine	.111	1.342	.214	.143

Intervention	units on a scale (Mean)
	Block 1 Baseline Week 0	Block 1 End of Treatment week 6	Block 1 End of Treatment Week 8	Blocks 2 End of Treatment Week 14
Atomoxetine Then Methylphenidate	.3224	.2386	.3526	.2118
Methylphenidate Then Atomoxetine	.3385	.1978	.3078	.2304

Intervention	units on a scale (Mean)
	Block 1 Baseline Week 0	Block 1 End of Treatment Week 6	Block 2 Baseline 8	Blocks 2 End of Treatment Week 14
Atomoxetine Then Methylphenidate	16.56	7.82	13.99	6.67
Methylphenidate Then Atomoxetine	17.31	7.24	14.80	8.87

Intervention	percentage of participants (Number)
	Treatment Preference of ATX	Treatment Preference of MPH
Atomoxetine Then Methylphenidate	41.8	50.5
Methylphenidate Then Atomoxetine	27.4	51.9

Intervention	percentiles (Mean)
	Weight (0 to 25th percentile) (N=46)	Weight (25th to 50th percentile) (N=58)	Weight (50th to 75th percentile) (N=50)	Weight (75th to 100th percentile) (N=97)	Height (0 to 25th percentile) (N=64)	Height (25th tp 50th percentile) (N=61)	Height (50th to 75th percentile) (N=55)	Height (75th to 100th percentile) (N=65)	BMI (0 to 25th percentile) (N=34)	BMI (25th to 50th percentile) (N=53)	BMI (50th to 75th percentile) (N=55)	BMI (75th to 100th percentile) (N=101)
Atomoxetine	18.93	14.90	-1.33	-6.68	12.06	9.53	-6.28	-10.92	18.71	8.52	-3.26	-7.94

Intervention	milliseconds (msec) (Mean)
	RR Interval	QRS Interval	QT Bazett (bz) Correction	QT Data (dat) Correction	QT Fridericia (fr) Correction
Atomoxetine	27.2	2.6	-1.7	-0.2	0.5

Intervention	units on a scale (Mean)
	CPRS ADHD Index Subscale (n=1056)	CPRS Cognitive Subscale (n=1056)	CPRS Hyperactive Subscale (n=1057)	CPRS Oppositional Subscale (n=1059)
Atomoxetine	2.411	1.500	0.325	1.357

Intervention	participants (Number)
	Systolic BP High (N=1431)	Diastolic BP High (N=1458)	Pulse High (N=1528)	Pulse Low (N=1528)	Temperature High (N=1525)	Temperature Low (N=1525)	Weight Decrease (N=1526)
Atomoxetine	228	92	19	39	7	9	61

Intervention	units on a scale (Mean)
	Total Score	Inattentive Subscale Score	Hyperactive Subscale Score
Atomoxetine	3.5	2.6	0.9

Intervention	participants (Number)
	QTc (bz) Normal Baseline/Normal Endpoint	QTc (bz) Normal Baseline/Borderline Endpoint	QTc (bz) Normal Baseline/Prolonged Endpoint	QTc (bz) Borderline Baseline/Normal Endpoint	QTc (bz) Borderline Baseline/Borderline Endpoint	QTc (bz) Borderline Baseline/Prolonged Endpoint	QTc (bz) Prolonged Baseline/Normal Endpoint	QTc (bz) Prolonged Baseline/Borderline Endpoint	QTc (bz) Prolonged Baseline/Prolonged Endpoint	QTc (dat) Normal Baseline/Normal Endpoint	QTc (dat) Normal Baseline/Borderline Endpoint	QTc (dat) Normal Baseline/Prolonged Endpoint	QTc (dat) Borderline Baseline/Normal Endpoint	QTc (dat) Borderline Baseline/Borderline Endpoint	QTc (dat) Borderline Baseline/Prolonged Endpoint	QTc (dat) Prolonged Baseline/Normal Endpoint	QTc (dat) Prolonged Baseline/Borderline Endpoint	QTc (dat) Prolonged Baseline/Prolonged Endpoint	QTc (fr) Normal Baseline/Normal Endpoint	QTc (fr) Normal Baseline/Borderline Endpoint	QTc (fr) Normal Baseline/Prolonged Endpoint	QTc (fr) Borderline Baseline/Normal Endpoint	QTc (fr) Borderline Baseline/Borderline Endpoint	QTc (fr) Borderline Baseline/Prolonged Endpoint	QTc (fr) Prolonged Baseline/Normal Endpoint	QTc (fr) Prolonged Baseline/Borderline Endpoint	QTc (fr) Prolonged Baseline/Prolonged Endpoint
Atomoxetine	1069	156	11	180	49	6	6	5	0	1433	26	1	16	3	1	2	0	0	1454	16	2	7	0	1	2	0	0

Intervention	participants (Number)
	QTc (bz) Increase of at least 30 milliseconds (ms)	QTc (bz) Increase of at least 60 ms	QTc (bz) Increase to values >500 ms	QTc (dat) Increase of at least 30 ms	QTc (dat) Increase of at least 60 ms	QTc (dat) Increase to values >500 ms	QTc (fr) Increase of at least 30 ms	QTc (fr) Increase of at least 60 ms	QTc (fr) Increase to values >500 ms
Atomoxetine	68	2	0	50	2	0	56	2	0

Intervention	participants (Number)
	AST/SGOT (U/L) Low (N=1484)	AST/SGOT (U/L) High (N=1484)	ALT/SGPT (U/L) Low (N=1486)	ALT/SGPT (U/L) High (N=1486)	Creatine Phosphokinase (U/L) Low (N=1485)	Creatine Phosphokinase (U/L) High (N=1485)	Alkaline Phosphatase (U/L) Low (N=1486)	Alkaline Phosphatase (U/L) High (N=1486)	Gamma Glutamyltransferase (U/L) Low (N=1486)	Gamma Glutamyltransferase (U/L) High (N=1486)	Urea Nitrogen (mmol/L) Low (N=1487)	Urea Nitrogen (mmol/L) High (N=1487)	Calcium (mmol/L) Low (N=1487)	Calcium (mmol/L) High (N=1487)	Inorganic Phosphorus (mmol/L) Low (N=1485)	Inorganic Phosphorus (mmol/L) High (N=1485)	Total Protein (g/L) Low (N=1487)	Total Protein (g/L) High (N=1487)	Albumin (g/L) Low (N=1487)	Albumin (g/L) High (N=1487)	Glucose, Non-Fasting/Random (mmol/L) Low (N=1486)	Glucose, Non-Fasting/Random (mmol/L) High (N=1486)	Uric Acid (umol/L) Low (N=1487)	Uric Acid (umol/L) High (N=1487)	Cholesterol (mmol/L) Low (N=1487)	Cholesterol (mmol/L) High (N=1487)	Creatinine (umol/L) Low (N=1487)	Creatinine (umol/L) High (N=1487)	Total Bilirubin (umol/L) Low (N=1458)	Total Bilirubin (umol/L) High (N=1458)	Hematocrit (1) Low (N=1482)	Hematocrit (1) High (N=1482)	Hemoglobin (mmL/L-Fe) Low (N=1482)	Hemoglobin (mmL/L-Fe) High (N=1482)	Erythrocyte Count (TI/L) Low (N=1482)	Erythrocyte Count (TI/L) High (N=1482)	Leukocyte Count (GI/L) Low (N=1482)	Leukocyte Count (GI/L) High (N=1482)	Bands (GI/L) Low (N=1482)	Bands (GI/L) High (N=1482)	Neutrophils, Segmented (GI/L) Low (N=1482)	Neutrophils, Segmented (GI/L) High (N=1482)	Lymphocytes (GI/L) Low (N=1482)	Lymphocytes (GI/L) High (N=1482)	Monocytes (GI/L) Low (N=1482)	Monocytes (GI/L) High (N=1482)	Eosinophils (GI/L) Low (N=1482)	Eosinophils (GI/L) High (N=1482)	Basophils (GI/L) Low (N=1482)	Basophils (GI/L) High (N=1482)	Mean Cell Volume (fL) Low (N=1482)	Mean Cell Volume (fL) High (N=1482)	Platelet Count (GI/L) Low (N=1479)	Platelet Count (GI/L) High (N=1479)	Sodium (mmol/L) Low (N=1486)	Sodium (mmol/L) High (N=1486)	Potassium (mmol/L) Low (N=1484)	Potassium (mmol/L) High (N=1484)	Chloride (mmol/L) Low (N=1486)	Chloride (mmol/L) High (N=1486)	Bicarbonate (mmol/L) Low (N=1486)	Bicarbonate (mmol/L) High (N=1486)	UA-Specific Gravity (no units) Low (N=1486)	UA-Specific Gravity (no units) High (N=1486)	Lymphocytes, Atypical (GI/L) Low (N=52)	Lymphocytes, Atypical (GI/L) High (N=52)
Atomoxetine	0	27	2	38	0	57	67	83	0	17	1	2	0	117	10	31	2	5	1	113	20	1	6	130	87	72	0	285	0	38	24	85	14	30	8	3	63	8	0	0	20	23	6	0	62	12	0	54	0	3	26	10	1	63	0	2	0	8	0	2	7	6	39	73	0	52

Intervention	participants (Number)
	First Tanner, Age Group 1, Tanner I (N=7)	First Tanner, Age Group 1, Tanner II (N=7)	First Tanner, Age Group 1, Tanner III (N=7)	First Tanner, Age Group 1, Tanner IV (N=7)	First Tanner, Age Group 1, Tanner V (N=7)	First Tanner, Age Group 2, Tanner I (N=14)	First Tanner, Age Group 2, Tanner II (N=14)	First Tanner, Age Group 2, Tanner III (N=14)	First Tanner, Age Group 2, Tanner IV (N=14)	First Tanner, Age Group 2, Tanner V (N=14)	First Tanner, Age Group 3, Tanner I (N=37)	First Tanner, Age Group 3, Tanner II (N=37)	First Tanner, Age Group 3, Tanner III (N=37)	First Tanner, Age Group 3, Tanner IV (N=37)	First Tanner, Age Group 3, Tanner V (N=37)	First Tanner, Age Group 4, Tanner I (N=35)	First Tanner, Age Group 4, Tanner II (N=35)	First Tanner, Age Group 4, Tanner III (N=35)	First Tanner, Age Group 4, Tanner IV (N=35)	First Tanner, Age Group 4, Tanner V (N=35)	Endpoint Tanner, Age Group 1, Tanner I (N=2)	Endpoint Tanner, Age Group 1, Tanner II (N=2)	Endpoint Tanner, Age Group 1, Tanner III (N=2)	Endpoint Tanner, Age Group 1, Tanner IV (N=2)	Endpoint Tanner, Age Group 1, Tanner V (N=2)	Endpoint Tanner, Age Group 2, Tanner I (N=4)	Endpoint Tanner, Age Group 2, Tanner II (N=4)	Endpoint Tanner, Age Group 2, Tanner III (N=4)	Endpoint Tanner, Age Group 2, Tanner IV (N=4)	Endpoint Tanner, Age Group 2, Tanner V (N=4)	Endpoint Tanner, Age Group 3, Tanner I (N=32)	Endpoint Tanner, Age Group 3, Tanner II (N=32)	Endpoint Tanner, Age Group 3, Tanner III (N=32)	Endpoint Tanner, Age Group 3, Tanner IV (N=32)	Endpoint Tanner, Age Group 3, Tanner V (N=32)	Endpoint Tanner, Age Group 4, Tanner I (N=55)	Endpoint Tanner, Age Group 4, Tanner II (N=55)	Endpoint Tanner, Age Group 4, Tanner III (N=55)	Endpoint Tanner, Age Group 4, Tanner IV (N=55)	Endpoint Tanner, Age Group 4, Tanner V (N=55)
Atomoxetine	2	2	2	1	0	4	6	2	2	0	0	2	13	15	7	0	0	2	11	22	1	1	0	0	0	0	1	2	1	0	0	5	8	14	5	0	0	3	19	33

Intervention	Units on a scale (Mean)
	Parent Domain Total	Parent Domain Competence	Parent Domain Isolation	Parent Domain Attachment	Parent Domain Health	Parent Domain Role Restriction	Parent Domain Depression	Parent Domain Spouse
Atomoxetine	-5.08	-1.78	-0.68	0.05	0.05	-0.51	-1.55	-0.74
Placebo	-1.34	-1.24	-0.11	0.40	-0.05	0.06	-0.08	-0.32

Intervention	Units on a scale (Mean)
	Total Stress	Life Stress
Atomoxetine	-10.74	0.25
Placebo	-7.06	-0.30

Intervention	Units on a scale (Mean)
	12 Weeks (n=235,202)	24 Weeks (n=236,202)
Atomoxetine	-0.69	-0.61
Placebo	0.14	0.36

Intervention	Units on a scale (Mean)
	Total Score 12 Weeks (n=233, 201)	Hyperactivity Score 12 Weeks (n=233, 202)	Inattention Score 12 Weeks (n=233, 201)	Total Score 24 Weeks (n=235, 202)	Hyperactivity Score 24 Weeks (n=235, 202)	Inattention Score 24 Weeks (n=235, 202)
Atomoxetine	-13.26	-5.84	-7.42	-13.66	-6.05	-7.62
Placebo	-9.06	-4.37	-4.66	-8.02	-3.68	-4.35

Intervention	Units on a scale (Mean)
	Total ADHD Symptoms Score (n=144, 119)	Hyper/Impulsive Subscale (n=144, 119)	Inattention Subscale (n=144, 119)	ADHD Index Subscale (n=143, 119)
Atomoxetine Group 1	-7.92	-3.21	-4.72	-4.65
Atomoxetine Group 2	-7.62	-3.51	-4.11	-4.30
Placebo	-5.12	-2.41	-2.71	-2.53

Intervention	Participants (Number)
	ODD Flag - Yes, Baseline	ODD Flag -No, Baseline	ODD Flag - Yes, 24 Weeks	ODD Flag -No, 24 Weeks	Conduct Disorder Flag - Yes, Baseline	Conduct Disorder Flag - No, Baseline	Conduct Disorder Flag - Yes, 24 Weeks	Conduct Disorder Flag - No, 24 Weeks
Atomoxetine	54	127	40	141	13	168	14	167
Placebo	40	119	33	126	14	145	10	149

Intervention	T-scores of units on a scale (Mean)
	Total Dyadic Adjustment	Dyadic Consensus	Dyadic Satisfaction	Affectional Expression	Dyadic Cohesion
Atomoxetine	1.13	1.61	0.52	1.16	-0.06
Placebo	0.70	1.42	-0.02	-0.85	0.54

atomoxetine hydrochloride

Description

Cross-References

Synonyms (98)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (1)

Protein Targets (24)

Potency Measurements

Inhibition Measurements

Biological Processes (176)

Molecular Functions (66)

Ceullar Components (38)

Bioassays (52)

Research

Studies (1,312)

Market Indicators

Research Demand Index: 63.20

Study Types

Clinical Trials (184)

Trial Overview

Trial Outcomes

The Adult AISRS

ADHD-Clinical Global Impression

Tics: Total Motor

Continuous Performance Test (CPT)

Children's Sleep Questionnaire

Clinical Global Impressions (CGI)- Severity

Child Conflict Index (CCI)

Assessment of Affective Range (AAR)

ADHD-RS Total Score

ADHD-RS Inattention

ADHD - H/I

Tics: Total Impairment

Vital Signs - Systolic Blood Pressure

Vital Signs - Pulse

Vital Signs - Diastolic Blood Pressure

Treatment Preference Survey

Tics: Total Phonic

Social Skills Rating Scale (SSRS)- Parent Version

Change From Baseline to 5 Year Endpoint in Weight, Height, and Body Mass Index (BMI) Percentile Stratified by Baseline Quartile

Change From Baseline to 5 Year Endpoint in Electrocardiogram (ECG)

Change From Baseline to 5 Year Endpoint in Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S) Subscale Scores

Change From Baseline to 5 Year Endpoint in Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity (CGI-ADHD-S) Score

Change From Baseline to 5 Year Endpoint in Heart Rate

Change From Baseline to 5 Year Endpoint in Height

Change From Baseline to 5 Year Endpoint in Pulse

Change From Baseline to 5 Year Endpoint in BP

Categorical Changes in Vital Signs (Blood Pressure [BP], Pulse, Weight, Temperature) During the Study

Change From Baseline to 5 Year Endpoint in Body Weight

Change From Baseline to 5 Year Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score and Subscale Scores

Number of Patients Meeting CPMP Categorical QTc Interval Criteria Part II (Interpretation at Baseline and Endpoint)

Number of Patients Meeting Committee for Proprietary Medicinal Products (CPMP) Categorical QTc Interval Criteria Part I (Numerical Increase)

Number of Participants With Abnormal Laboratory Analytes During the Study

Number of Participants in Each Tanner Stage (Pubic Hair) by Age Group

Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Parent Domains

Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Total Stress and Life Stress

Change From Baseline to 12 and 24 Weeks in the Montgomery-Asberg Depression Rating Scale Total Score (MADRS)

Change From Baseline to 12 and 24 Weeks in the Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale Total and Subscale Scores

Change From Baseline to 1 Week of Titration in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores

Change From Baseline to 24 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptoms Score

Mean Change From Baseline to 24 Weeks in the Child Disruptive Behavior Rating Scale (CDBRS) Parent Form Oppositional Defiant Disorder (ODD) and Conduct Disorder Flags

Change From Baseline to 8 Weeks in the Dyadic Adjustment Scale (DAS) - Participant

Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Child Domains

Change From Baseline to 12 Weeks in the Alabama Parenting Questionnaire (APQ) Parent Form

Change From Baseline to After a 2-Week Titration Period Beginning at Week 24 and Ending at Week 26 in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores: Dosing Titration Strategy After Placebo

Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Parent Domains

Change From Baseline to 8 Weeks in the Dyadic Adjustment Scale (DAS) - Spouse/Significant Other

Change From Baseline to 12 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptoms Score

Change From Baseline to 8 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Participant

Change From Baseline to 8 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Spouse/Significant Other

Mean Change From Baseline to 24 Weeks in the Child Disruptive Behavior Rating Scale (CDBRS) Parent Form

Change From Baseline to 8 Weeks in the Parenting Sense of Competence (PSOC) Scale

Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Child Domains

Intervention	Units on a scale (Mean)
	Child Domain Total	Defensive Responding	Child Domain Distractibility/Hyperactive	Child Domain Adaptability	Child Domain Reinforces Parent	Child Domain Demandingness	Child Domain Mood	Child Domain Acceptability
Atomoxetine	-5.66	-1.66	-1.70	-1.56	-0.79	-0.56	-0.36	-0.68
Placebo	-5.72	-0.35	-1.93	-1.87	-0.32	-1.00	-0.26	-0.34

Intervention	Units on a scale (Mean)
	Parent Involvement (n=230, 192)	Parent Positive Parenting (n=230, 192)	Parent Poor Supervision (n=229, 191)	Parent Inconsistent Discipline (n=230, 192)	Parent Corporal Punishment (n=230, 192)	Parent Other Discipline Practice (n=230, 190)	Dysfunctional Parenting Composite (n=229, 191)	Negative Parenting Composite (n=229, 191)	Positive Parenting Composite (n=230, 192)
Atomoxetine	0.27	0.00	-1.29	-1.07	-0.23	-0.01	-0.23	-0.37	0.03
Placebo	0.67	0.36	-1.17	-0.81	-0.21	0.00	-0.26	-0.32	0.13

Intervention	Units on a scale (Mean)
	Total ADHD Symptoms Score	Hyper/Impulsive Subscale	Inattention Subscale	ADHD Index Subscale
Atomoxetine	-0.17	-0.06	-0.12	-0.17
Placebo/Atomoxetine Group 1	-4.54	-1.71	-2.82	-2.37
Placebo/Atomoxetine Group 2	-4.92	-2.00	-2.92	-2.91

Intervention	T-scores of units on a scale (Mean)
	Task Accomplishment	Role Performance	Communication	Affective Expression	Involvement	Control	Values and Norms
Atomoxetine	-0.79	-0.25	-0.63	0.50	-0.27	-0.01	0.00
Placebo	-0.41	-0.04	-0.29	-0.33	0.17	0.33	-0.27

Intervention	Units on a scale (Mean)
	Total ADHD Score	Hyperactive-Impulsive Symptom ADHD Score	Inattention Symptom ADHD Score
Atomoxetine	-2.93	-1.18	-1.75
Placebo	-2.57	-1.26	-1.30

Intervention	Units on a scale (Mean)
	Total Score	Satisfaction Scale	Efficacy Scale
Atomoxetine	3.51	1.77	1.75
Placebo	2.52	1.26	1.25

Intervention	Units on a scale (Mean)
	Child Involvement Mother (n=189, 159)	Child Involvement Father (n=188, 159)	Child Positive Parenting (n=188, 159)	Child Poor Supervision (n=188, 158)	Child Inconsistent Discipline (n=189, 159)	Child Corporal Punishment (n=189, 160)	Child Other Discipline Practice (n=189, 159)
Atomoxetine	0.12	0.36	-0.90	-1.52	-0.44	-0.25	-0.24
Placebo	-0.11	0.44	-0.33	-1.31	-0.86	-0.34	-0.19

Intervention	Units on a scale (Mean)
	State Anxiety Score 12 Weeks (n=230, 197)	Trait Anxiety Score 12 Weeks (n=231, 198)	State Anxiety Score 24 Weeks (n=232, 198)	Trait Anxiety Score 24 Weeks (n=233, 198)
Atomoxetine	-1.50	-5.67	-0.40	-5.32
Placebo	1.12	-2.42	0.38	-2.77

Intervention	Units on a scale (Mean)
	Child Involvement Mother (n=189, 158)	Child Involvement Father (n=188, 159)	Child Positive Parenting (n=188, 159)	Child Poor Supervision (n=188, 158)	Child Inconsistent Discipline (n=189,159)	Child Corporal Punishment (n=189, 160)	Child Other Discipline Practice (n=189, 159)
Atomoxetine	0.08	0.38	-0.80	-1.12	-0.60	-0.30	-0.24
Placebo	-0.17	-0.15	-0.24	-1.23	-0.81	-0.31	-0.27

Intervention	Units on a scale (Mean)
	Total Score 6 Months (n=228)	Total Score 12 Months (n=178)	Total Score 2 Years (n=143)	Total Score 3 Years (n=105)	Total Score 4 Years (n=62)
Atomoxetine	-14.1	-16.0	-17.7	-20.0	-20.1